Patent Grant
11717326
This application relates generally to skin treatment, and more specifically, to apparatuses, systems and methods for treating a person's skin.
Abrasion of the outer layer or epidermis of the skin is desirable to smooth or blend scars, blemishes, or other skin conditions that may be caused by, for example, acne, sun exposure, and aging. Standard techniques used to abrade the skin have generally been separated into two fields referred to as dermabrasion and microdermabrasion. Both techniques remove portions of the epidermis called the stratum corneum, which the body interprets as a mild injury. The body then replaces the lost skin cells, resulting in a new outer layer of skin. Additionally, despite the mild edema and erythema associated with the procedures, the skin looks and feels smoother because of the new outer layer of skin.
According to some embodiments, a method of treating a skin surface of a subject comprises heating a skin surface, abrading native skin tissue of a subject using a microdermabrasion device, wherein using the microdermabrasion device comprises moving the microdermabrasion device relative to the skin surface while simultaneously delivering at least one treatment fluid to the skin surface being treated and cooling the abraded skin surface.
According to some embodiments, heating and cooling the skin surface is performed using a thermal conditioning handheld assembly. In one embodiment, the thermal conditioning handheld assembly is configured to be selectively heated or cooled conductively (e.g., using at least one thermoelectric device) within a thermal recharging station. In some embodiments, the at least one treatment fluid is delivered to the skin surface using and through the microdermabrasion device. The method further comprising exposing the skin surface to at least one additional treatment (e.g., exposure to a source of energy, such as, radiofrequency, ultrasound, microwave, laser, etc.).
According to some embodiments, a skin surface of a subject comprising abrading native skin tissue of a subject using a microdermabrasion device, wherein using the microdermabrasion device comprises moving the microdermabrasion device relative to the skin surface while simultaneously delivering at least one treatment fluid to the skin surface being treated and exposing the skin surface to at least one additional treatment procedure.
According to some embodiments, the at least one additional treatment procedure comprises exposing the skin surface to an energy source. In one embodiment, the energy source comprises at least one of radiofrequency, ultrasound, microwave, laser and/or the like. In some embodiments, the at least one additional treatment procedure comprises delivering air to the skin surface. In some embodiments, air is delivered to the skin surface by and through the microdermabrasion device. In one embodiment, the at least one additional treatment procedure comprises exposing the skin surface to light. In some embodiments, the at least one additional treatment procedure comprises heating or cooling the skin surface.
According to some embodiments, a microdermabrasion device for treating skin comprises a handpiece assembly having a distal end and a proximal end. The handpiece assembly includes at least one delivery conduit and at least one waste conduit. The microdermabrasion device additionally comprises a tip configured to be positioned along the distal end of the handpiece assembly, wherein the tip is adapted to contact skin surface. According to some embodiments, the microdermabrasion device further includes a flow control device or feature included within the handpiece assembly to regulate the flow of fluids through the delivery conduit. In several embodiments, the tip comprises a lip, a first opening in fluid communication with the fluid delivery conduit and a second opening in fluid communication with the waste conduit. In one embodiment, the device includes one or more abrasive elements positioned along a distal end of the tip, wherein the abrasive elements are configured to selectively remove skin as the tip is moved relative to a skin surface. In some embodiments, the first opening, the second opening and the abrasive elements of the tip are positioned within an interior of an outer periphery formed by the lip. In some embodiments, the waste conduit is in fluid communication with a vacuum source to selectively remove debris away from the tip. In one embodiment, the delivery conduit is in fluid communication with the at least one waste conduit and the vacuum source when the lip contacts a skin surface. In some embodiments, the delivery conduit is configured to selectively deliver at least one time-release material to the skin surface being treated.
According to some embodiments, the flow control device comprises a valve (e.g., a needle valve). In some embodiments, the abrasive element comprises a protruding member, a spiral ridge or an abrasive surface. In other embodiments, the abrasive element comprises an abrasive disc, an abrasive surface and/or any other member that is configured to be separated from the tip or that is configured to be permanently attached to the tip. In one embodiment, the tip is removable from the handpiece assembly. In other embodiments, the time-release material comprises a plurality of microcapsules, capsules or other enclosures configured to release their internal contents at various times following delivery to the skin surface. In some embodiments, the time-release material comprises salicylic acid. In other embodiments, the time-release material comprises one or more other active and/or non-active ingredients (e.g., azelaic acid, topical retinoids, benzoyl peroxide, topical antibiotics, other anti-acne materials, saline, other dilutants or fluids, soaps, hardening agents, gels, other binders, lotions, moisturizers, peptides, amino acids, UVA and/or UVB sunblocks, other sunblocking agents, skin tightening agents, hyaluronic acid (HA), other hydration agents, hair removal or hair growth suppression agents, medicaments and pharmaceuticals, etc.), either alone or in combination with one another.
In one embodiment, the time-release material is impregnated along at least a portion of the tip. In other embodiments, the time-release material is initially contained within a cartridge or other container that is in fluid communication with the delivery conduit when the cartridge or other container is secured to the handpiece assembly. In other embodiments, the time release material is delivered to the tip of the handpiece without any prior dilution or premixing. In some embodiments, the handpiece assembly comprises a recess configured to removably receive a cartridge, wherein an internal content of the cartridge is placed in fluid communication with the delivery conduit when the cartridge is secured within the recess of the handpiece assembly. In some embodiments, the cartridge or container comprises a movable piston therein, wherein the movable piston configured to urge an internal content of the cartridge toward an outlet of the cartridge. In some embodiments, the cartridge or container comprises an airless pump design or configuration. In one embodiment, the time-release material is configured to treat a skin disorder or condition (e.g., acne, oily or dry skin, etc.).
According to certain arrangements, a device for treating a skin surface includes a handpiece assembly having a distal end and a proximal end such that the handpiece assembly comprises at least one delivery conduit and at least one waste conduit. The device additionally comprises a tip configured to be positioned along the distal end of the handpiece assembly, such that the tip is adapted to contact the skin surface being treated. According to certain embodiments, the tip comprises a peripheral lip, a first opening in fluid communication with the fluid delivery conduit and a second opening in fluid communication with the waste conduit and an abrasive element or surface positioned along a distal end of the tip, said abrasive element or surface configured to remove skin. In one embodiment, the first opening, the second opening and the abrasive element of the disc are positioned along an interior of the peripheral lip. In another arrangement, one or more waste conduits are configured to be in fluid communication with a vacuum to selectively remove debris away from the tip. In other configurations, a delivery conduit is placed in fluid communication with the waste conduit and the vacuum when the peripheral lip contacts a skin surface. In yet other embodiments, one or more time-release materials are configured to be delivered to the skin surface being treated.
In some embodiments, the handpiece assembly comprises a housing having a clamshell design. In one embodiment, a housing of the handpiece assembly comprises two or more portions that are configured to removably or permanently attach to each other (e.g., using screws, other fasteners, snap fit or friction fit connections, adhesives, welds and/or any other connection method or device). In some embodiments, the two or more portions of the housing are configured to be manufactured using an injection molding procedure or any other molding or manufacturing process (e.g., compression molding, thermoforming, extrusion, etc.). In one embodiment, the two portions or more portions of the housing comprise a plastic, metal, alloy and/or any other synthetic or natural material.
According to other embodiments, the device additionally includes a valve configured to control a flowrate of a fluid being delivered through the fluid delivery conduit to the tip. In another arrangement, the abrasive element or structure comprises one or more protruding members, spiral ridges and/or abrasive surfaces. In certain embodiments, the time-release material comprises a plurality of microcapsules or capsules configured to release their internal contents at various times following delivery to the skin surface. In one embodiment, the time-release materials comprise one or more of the following: peptides, amino acids, UVA and/or UVB sunblocks, other sunblocking agents, skin tightening agents, hyaluronic acid (HA), other hydration agents, hair removal or hair growth suppression agents, medicaments and pharmaceuticals, combinations thereof and/or any other substance. In other arrangements, time-release materials are impregnated along at least a portion of the tip. In yet other embodiments, the cartridge or other container is in fluid communication with the handpiece assembly. In certain embodiments, the time-release materials are configured to be released to the skin surface after contact with water or another dilutant. In other arrangements, the time-release materials are configured to treat acne or another skin disorder.
According to certain embodiments of the present application, a handpiece assembly for treating a skin surface comprises a recess configured to receive a cartridge or other container. The cartridge or other container comprises one or more treatment materials, such as, for example, human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, brightening or lightening agents, peptides, acids, anesthetics, medicants, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance. In one embodiment, the handpiece assembly comprises a valve or other flow control device or feature to enable a user to selectively regulate a flowrate of a treatment material through the handpiece assembly. In other embodiments, the cartridge or other container comprises an inlet configured to be in fluid communication with water, saline, another dilutant or dissolvent or another fluid. The water, saline, another dilutant or dissolvent or another fluid is configured to be delivered through the inlet and to an interior of the cartridge so as to mix or combine with a treatment material contained therein. In some embodiments, the treatment material contained within the cartridge or container is a liquid, solid, gel, granulated material or concentrated solution. In some embodiments, one or more treatment fluids are conveyed from an outlet of the cartridge or container to a tip attached to a distal end of the handpiece assembly.
According to certain arrangements, treatment materials that are provided to the skin interface during a dermabrasion procedure are configured to be released or otherwise made available to a user's skin over a pre-selected, relatively extended time period. Such time release materials can be provided in the form of microcapsules, other capsules or enclosures and/or the like.
Regardless of the form in which they are provided (e.g., within microcapsules or other enclosures), time-release products or materials can be delivered to a skin surface directly through a cartridge or other container. Such a cartridge can be positioned within a handpiece assembly, such as, for example, those illustrated in
In yet other arrangements, time-release materials are advantageously provided, either alone or in combination with one or more other substances, within a recess, cavity or other opening or a tip or other portion of a skin treatment system. For example, such recesses can be provided along a distal surface of the tip, as illustrated in
Regardless of where the time-release materials are positioned relative to the handpiece assembly (e.g., within a cartridge or other container, within or outside of a handpiece assembly, in a recess or other opening of a tip or other portion of a handpiece assembly, within a foam pad, on a surface of a tip or other portion of a handpiece assembly, etc.), water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants and/or other fluids can be used to selectively dissolve, liquefy, melt, soften, dilute or otherwise prepare the time-release and/or any other materials. Accordingly, the desired salicylic acid, other anti-acne materials, human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, water, saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, brightening or lightening agents, peptides, amino acids, other acids, anesthetics, UVA and/or UVB sunblocks, other sunblocking agents, skin tightening agents, hyaluronic acid (HA), other hydration agents, hair removal or hair growth suppression agents, medicaments and pharmaceuticals, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance can be advantageously provided to the skin surface being treated, as desired or required.
According to certain embodiments, time-release materials include one or more active ingredients that target specific skin conditions or types. For instance, a time-release product used to help control skin acne can include salicylic acid. The salicylic acid can be provided alone or in combination with one or more other active and/or non-active ingredients (e.g., azelaic acid, topical retinoids, benzoyl peroxide, topical antibiotics, other anti-acne materials, saline, other dilutants or fluids, soaps, hardening agents, gels, other binders, lotions, moisturizers, peptides, amino acids, UVA and/or UVB sunblocks, other sunblocking agents, skin tightening agents, hyaluronic acid (HA), other hydration agents, hair removal or hair growth suppression agents, medicaments and pharmaceuticals, etc.).
Time-release salicylic acid capsules (e.g., microcapsules) and/or any other active or non-active ingredients included in a skin treatment material can be encapsulated within a solid binder, such as, for example, soap or gel. Thus, when water or another fluid is added to the material, the treatment material can at least partially dissolve, advantageously releasing capsules onto the skin surface. The capsules can be configured to release their internal contents at different time intervals after being deposited on or near a person's skin.
Alternatively, as discussed in greater detail herein, such microcapsules or other time-release materials can be provided within a cartridge, another container, a recess or other opening and/or the like. According to certain embodiments, the microcapsules or other time-release materials are included within a binder or are provided in loose form (e.g., as a solid, within a liquid, gel, other fluid or other medium, etc.). Thus, time-release materials can be selectively delivered to the skin (or be initially present at a tip-skin interface) in one or more different forms. Regardless of the exact manner in which they are provided to a person's skin, such time-release materials can help target certain skin ailments or conditions (e.g., acne, eczema, psoriasis, etc.), conditions (e.g., dry skin, oily skin, etc.) and/or the like.
In some embodiments, microcapsules and/or other time-release products delivered to the skin surface are configured to be released or otherwise become available to the skin at different times from each other. For example, microcapsules can be adapted to release salicylic acid and/or any other active or non-active ingredients contained therein in various time intervals (e.g., quarter-hour, half-hour, one-hour, two-hour, three-hour, etc.). Accordingly, the desired materials can be provided to a target skin surface to have an effect on such a surface over a longer period of time. This can facilitate a particular treatment procedure by effectively prolonging the overall treatment time-period. For example, in some embodiments, an acne treatment is more effective if salicylic acid is released over a targeted skin surface during a longer time period (e.g., less than 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours, more than 48 hours, etc.).
In one embodiment, time-release materials are provided to a dermabrasion system which is adapted to treat skin having acne or another skin condition. A handpiece assembly having an abrasive distal end, such as, for example, a tip in accordance with any of the arrangements illustrated or otherwise disclosed herein, or equivalents thereof, can be used to treat a skin surface of a patient. As the tip is moved across the target skin area, exfoliated skin, infected waste and/or other materials can be advantageously removed. In addition, the treatment system can be configured to selectively deposit time-release product onto the treated skin before, after and/or contemporaneously with the exfoliation process. As discussed in greater detail herein, the time-release product can be delivered from a cartridge or other container located either within a handpiece assembly or separate from it. In some arrangements, water, saline and/or other dilutants are required to at least partially dissolve or otherwise release such substances (e.g., from a binder, gel, solid, etc.). Salicylic acid and/or any other materials contained within the time-release product (e.g., microcapsules, other capsules, caps, etc.) and/or other materials delivered to the patient's skin can be advantageously released over a longer time-period so as to help prevent or reduce the likelihood of bacterial infection, pain or discomfort, sensitivity to sunlight or other light sources and/or the like.
According to certain arrangements, time-release capsules or other materials containing salicylic acid and/or other skin solutions can be embedded on or near a surface of a tip using a binder. For example, glycerin soap or other base materials or hardening agents can be used to bind the time-release materials. As water, saline or other dilutants or fluids are selectively delivered to the bound materials, time-release materials can dissolve, allowing salicylic acid capsules to be released to a target area of the skin. In one configuration, the time-release materials comprise approximately 30% of the bound mixture by volume, while the soap or other base material and/or hardening agent comprises the remaining approximately 70%. In other embodiments, the volumetric ratio of time-release materials to base materials and hardening agents can be greater or less than 3:7, as required or desired (e.g., less than approximately 1:9, approximately 1:4, 2:3, 1:1, 3:2, 7:3, 4:1, more than approximately 4:1, etc.).
According to certain arrangements, a disc, plate or other member having diamonds or any other abrasive element is removably positioned within an interior region of the tip (e.g., generally between the tip and adjustable distal portion or any other component of the handpiece assembly). Such a disc, which is configured to contact and abrade skin through one or more openings of the tip, can be conveniently removed for cleaning, replacement and/or any other purpose
According to other embodiments, a treatment material disposed on or near the tip of the handpiece assembly is configured to be mixed or combined with water, saline or another fluid being delivered through the handpiece assembly to create a treatment fluid. In certain embodiments, the treatment material is provided as a solid, semi-solid, gel, granulated material or concentrated fluid or solution. In some arrangements, the treatment material is positioned within a recess of the tip, between the tip and a main body portion of the handpiece assembly or within the main body portion of the handpiece assembly. In some embodiments, water, saline, treatment fluid or other fluid being conveyed through the handpiece assembly is configured to be heated.
According to certain embodiments of the present application, a device for treating a skin surface comprises a handpiece assembly having a distal end and a proximal end. The handpiece assembly comprises at least one delivery conduit and at least one waste conduit. The handpiece assembly further comprising a recess or other opening configured to receive a cartridge or other container having an interior cavity. In one embodiment, the interior cavity of the cartridge is placed in fluid communication with the fluid delivery conduit when the cartridge is secured within the recess. The device additionally includes a tip positioned along the distal end of the handpiece assembly, such that the tip is configured to contact the skin surface. In certain embodiments, the tip comprises a peripheral lip, a first opening in fluid communication with the fluid delivery conduit and a second opening in fluid communication with the waste conduit and an abrasive element. The first opening, the second opening and the abrasive element are generally positioned along an interior of the peripheral lip. In one embodiment, the waste conduit is configured to be in fluid communication with a vacuum to selectively remove debris away from the tip. In other arrangements, the delivery conduit is placed in fluid communication with the waste conduit and the vacuum when the peripheral lip contacts a skin surface.
In certain arrangements, the device further includes a valve generally positioned between the interior cavity of the cartridge and the fluid delivery conduit. The valve can be adapted to control the flowrate of a fluid being conveyed from the interior cavity of the cartridge to the tip. In other embodiments, the handpiece assembly comprises an adjustable intermediate space positioned generally between the interior cavity of the cartridge and the fluid delivery conduit. In one arrangement, a volume of the adjustable intermediate space can be selectively modified by moving an actuator on the handpiece assembly. In other configurations, the handpiece assembly comprises a stem in fluid communication with the fluid delivery conduit. The stem can be adapted to extend into the interior cavity of a cartridge when the cartridge is positioned with the recess of the handpiece assembly. In other embodiments, the tip is selectively removable from the handpiece assembly. In one arrangement, the abrasive element comprises a plurality of posts, other protruding members, a spiral-shaped ridge, an abrasive surface, a foam pad, another type of pad and/or the like. In some arrangements, the device further includes a heating element configured to selectively heat a fluid being conveyed through the delivery conduit, another interior passage or conduit of the handpiece assembly, the tip, an inlet line and/or the like. In other embodiments, the cartridge comprises an inlet configured to be placed in fluid communication with a delivery source.
According to other arrangements, a skin treatment system includes a handpiece assembly having a distal end and a proximal end. The handpiece assembly comprises a fluid delivery conduit. In one embodiment, the handpiece assembly comprises a first portion and a second portion, with the first portion being selectively movable relative to the second portion. The skin treatment system further includes a tip adapted to contact skin and positioned on the distal end of the handpiece assembly. In one embodiment, the tip comprises a first opening, which is in fluid communication with the fluid delivery conduit, and an abrasive element. The system further comprises an intermediate space generally defined between the first and second portions of the handpiece assembly. Movement of the first portion with respect to the second portion can modify the volume of the intermediate space and generally control the flowrate of a fluid being conveyed through the fluid delivery conduit. In some embodiments, the system further includes an actuator on the handpiece assembly for moving the first portion relative to the second portion.
According to other embodiments, movement of the first portion with respect to the second portion is produced by rotating the second portion relative to the first portion. In some arrangements, the tip is selectively removable from the second portion. In another adaptation, the tip comprises a plurality of posts or protruding members configured to treat skin. In other arrangements, the tip comprises one or more ridges (e.g., spiral-shaped ridges), abrasive surfaces or elements and/or other features or components configured to treat skin. In certain embodiments, the handpiece assembly further comprises a waste channel in fluid communication with a second opening in the tip. In another embodiment, the handpiece assembly includes a recessed area configured to receive a cartridge comprising at least one treatment fluid or material. In other arrangements, the cartridge includes an interior portion which is at least partially defined by a membrane. The membrane can be configured to be pierced by a hollow spike of the first portion of the handpiece assembly when the cartridge is properly inserted within the recessed area, so that the hollow spike is placed in fluid communication with the delivery channel. In certain configurations, the interior portion of the cartridge comprises human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, brightening or lightening agents, peptides, acids, anesthetics, medicants, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance. In other arrangements, the device comprises a heater configured to selectively heat a fluid being conveyed through the fluid delivery conduit toward the tip.
According to certain embodiments, a method of providing a treatment fluid to a skin surface while treating said skin surface with a handpiece device includes providing at least one treatment material on or within a handpiece device. In one arrangement, a tip is configured to be removably positioned along a distal end of a main body portion of the handpiece assembly. The tip can be adapted to abrade or otherwise treat skin when moved relative to a skin surface. The treatment method additionally includes directing a first fluid through a delivery passage of the handpiece assembly so that said delivery passage generally contacts at least one treatment material of the tip. In some arrangements, the treatment material is configured to at least partially dissolve, dilute or combine with the first fluid so as to create a desired treatment fluid. Further, the treatment fluid can be configured to be provided to the tip and to the skin surface being treated while a distal end of the tip is being translated over said skin surface.
In some arrangements, the treatment material comprises a solid, granular material, gel or concentrated solution and/or any other material. In other embodiments, the first fluid comprises water (e.g., sterile, tap, distilled, filtered, etc.), saline, other dilutants or dissolvents and/or any other fluid. In other arrangements, the treatment fluid comprises human growth factors, cytokines, soluble collagen, antioxidants or matrix proteins. In another embodiment, the treatment material is positioned in or near the tip, such as, for example, within a post, other protruding member, other recess, underneath the tip and/or like. In other arrangements, the treatment material comprises a disc, tablet, capsule, granular material, gel and/or the like. In one embodiment, the treatment material is configured to be positioned within a cage or other porous container. In other arrangements, the disc, table, capsule or other treatment material is configured to be secured generally between the main body portion and the tip of the handpiece assembly. In one configuration, the method further includes regulating a flowrate of the first fluid by selectively controlling a valve on the handpiece assembly. In another arrangement, the method additionally includes selectively heating the first fluid using a heating member positioned in thermal communication with the delivery passage of the handpiece assembly. In some embodiments, the treatment material is positioned within a cartridge which is configured to be removably secured to a receiving area of the handpiece assembly.
According to some embodiments disclosed in the present application, a device for treating the skin comprises a handpiece assembly having a distal end and a proximal end, a cartridge comprising an interior cavity and a tip on the distal end of the handpiece assembly. The handpiece assembly includes a fluid delivery conduit and a waste conduit. In addition, the cartridge is coupled to the handpiece assembly, with the interior cavity of the cartridge being in fluid communication with the fluid delivery conduit. Further, the tip is configured to contact the skin. The tip comprises a peripheral lip, a first opening in fluid communication with the fluid delivery conduit, a second opening in fluid communication with the waste conduit and an abrasive element. The first opening, the second opening and the abrasive element of the tip are generally positioned within the peripheral lip.
In some embodiments, the device further comprises a valve positioned between the interior cavity of the cartridge and the fluid delivery conduit. In one embodiment, the handpiece assembly comprises an adjustable intermediate space positioned generally between the interior cavity of the cartridge and the fluid delivery conduit. In another arrangement, a volume of the adjustable intermediate space can be selectively modified by moving an actuator on the handpiece assembly. In other embodiments, the handpiece assembly comprises a recessed area configured to receive the cartridge.
According to other embodiments, the handpiece assembly comprises a stem that is in fluid communication with the fluid delivery conduit as the stem is configured to extend into the interior cavity of a cartridge when the cartridge is coupled to the handpiece assembly. In another embodiment, the tip is selectively removable from the handpiece assembly. In some arrangements, the abrasive element comprises a plurality of protruding members. In other embodiments, the tip comprises an abrasive edge.
According to another embodiment, a system for treating the skin comprises a handpiece assembly having a distal end and a proximal end and a tip on the distal end of the handpiece assembly configured to contact the skin. The handpiece assembly includes a fluid delivery conduit and first and second portions. Further, the tip includes a first opening in fluid communication with the fluid delivery conduit and an abrasive element. An intermediate space generally defined between the first and second portions of the handpiece assembly is in fluid communication with the fluid delivery conduit. In one embodiment, movement of the first portion with respect to the second portion modifies the volume of the intermediate space to control a flowrate through the fluid delivery conduit. The system further comprises an actuator on the handpiece assembly for actuating movement between the first portion and the second portion.
In some embodiments, movement of the first portion with respect to the second portion is produced by rotating the second portion relative to the first portion. In other embodiments, the tip is selectively removable from the second portion. In still other arrangements, the tip comprises a plurality of protruding members configured to treat skin. In another embodiment, the tip comprises an abrasive surface configured to treat skin.
According to some embodiments, the handpiece assembly further comprises a waste channel in fluid communication with a second opening in the tip. In another arrangement, the handpiece assembly includes a recessed area configured to receive a cartridge comprising at least one treatment fluid or material. In other embodiments, the cartridge includes an interior portion at least partially defined by a membrane. The membrane is configured to be pierced by a hollow spike of the first portion of the handpiece assembly. Further, the hollow spike is in fluid communication with the delivery channel. In one embodiment, the interior portion of the cartridge comprises human growth factors, cytokines, soluble collagen, antioxidants and/or matrix proteins.
According to other embodiments, the present application discloses a method for treating the skin of a patient with a skin treatment device having a working end that includes an abrading structure configured to engage and abrade skin. The method includes placing the working end of the skin treatment device against the skin of the patient, translating the working end over the skin to abrade a skin surface, providing a treatment fluid to the skin through an opening in the working end and aspirating skin debris from the skin surface through an aspiration opening in the working end of the skin treatment device. In some embodiments, the treatment fluid comprises human growth factors, cytokines, soluble collagen, antioxidants and/or matrix proteins.
According to some embodiments disclosed in the present application, a device for treating the skin comprises a handpiece assembly having a distal end and a proximal end. The handpiece assembly includes a fluid delivery conduit and a waste conduit. In addition, the handpiece assembly is adapted to receive a cartridge having an interior cavity. Further, the device includes a tip attached to the distal end of the handpiece assembly and comprising a surface configured to treat skin. The waste conduit is configured to be in fluid communication with a vacuum source and the fluid delivery conduit is configured to be in fluid communication with an interior cavity of a cartridge when a cartridge is secured to the handpiece assembly.
In some embodiments, the handpiece assembly comprises a flow control feature configured to selectively regulate a flowrate through the fluid delivery conduit. In another arrangement, the handpiece assembly includes a main body portion and an adjustable portion attached to the main body portion. The flow control feature can comprise an adjustable intermediate space generally located between the main body portion and the adjustable portion. In other embodiments, a volume of the adjustable intermediate space can be selectively modified by moving the main body portion relative to the adjustable portion of the handpiece assembly.
In one embodiment, the handpiece assembly comprises a recessed area configured to secure a cartridge. In another arrangement, the handpiece assembly comprises a stem adapted to access an interior cavity of a cartridge when a cartridge is secured to the handpiece assembly. According to some embodiments, the tip is selectively removable from the handpiece assembly. In other embodiments, the tip comprises a plurality of protruding members configured to treat skin. In still other arrangements, the tip comprises an abrasive surface configured to treat skin.
According to another embodiment, a system for treating the skin includes a handpiece assembly. The handpiece assembly comprises a tip configured to treat skin, a first portion and a second portion. The first portion includes a delivery conduit, which has a first longitudinal axis, and is configured to be in fluid communication with at least one fluid source. Further, the second portion includes a distal end and a proximal end, with the proximal end being attached to the main body portion and the distal end being attached to the tip. The second portion includes a delivery channel having a second longitudinal axis and being in fluid communication with the tip and the delivery conduit. In addition, the second portion further comprises a removal channel being in fluid communication with the tip and a suction source. In some embodiments, an intermediate space is generally defined between the first and second portions of the handpiece assembly. Such an intermediate space is in fluid communication with the delivery conduit of the first portion and the delivery channel of the second portion. Further, a volume of the intermediate space is configured to be adjusted by selectively modifying a separation distance between the first portion and the second portion. Accordingly, a flowrate from a fluid source to the tip can be selectively controlled by modifying the separation distance between the first portion and the second portion.
In some embodiments, the separation distance between the first portion and the second portion is modified by rotating the second portion relative to the first portion. In other arrangements, the first longitudinal axis of the delivery conduit is generally offset with the second longitudinal axis of the delivery channel. In one embodiment, the tip is selectively removable from the second portion.
According to some embodiments, the tip comprises a plurality of protruding members configured to treat skin. In other embodiments, the tip comprises an abrasive surface configured to treat skin. In one embodiment, the first portion further comprises a waste channel in fluid communication with the removal channel of the second portion. In another arrangement, the first portion includes a recessed area configured to receive a cartridge comprising at least one treatment fluid or material. In some embodiments, the cartridge includes an interior portion at least partially defined by a membrane which is configured to be pierced by a hollow spike of the first portion of the handpiece assembly. The hollow spike is in fluid communication with the delivery channel. According to other embodiments, the cartridge the interior portion of the cartridge comprises human growth factors, cytokines, soluble collagen, antioxidants or matrix proteins.
According to other embodiments disclosed in the present application, a method of treating the skin comprises providing a handpiece assembly comprising a body and a tip having a distal end. The handpiece assembly includes a delivery conduit and a waste conduit that are in fluid communication with the distal end of the tip. The method further includes placing the delivery conduit of the handpiece assembly in fluid communication with a fluid source for providing at least one treatment fluid to the distal end of the tip and placing the waste conduit of the handpiece assembly in fluid communication with a suction source for removing waste materials from the distal end of the tip. In addition, the method comprises moving the handpiece assembly along a person's skin and activating the suction source to remove a volume of waste materials from the distal end of the tip and to simultaneously deliver a volume of the treatment fluid to the distal end of the tip. In one embodiment, the flowrate at which treatment fluids and/or other materials are delivered to the tip can be varied by a valve or other flow control feature of the handpiece assembly. In some embodiments, the treatment fluid comprises human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, brightening or lightening agents (e.g., kojic acid), peptides, acids, anesthetics, medicants, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance.
Certain embodiments are disclosed herein having reference to the figures that follow.
As shown in
With continued reference to
In some embodiments, the vial or cartridge 200 comprises one or more of the following: human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances (e.g., capsules, microcapsules, etc.), water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, brightening or lightening agents (e.g., kojic acid), numbing agents, peptides, acids, anesthetics (e.g., Lidocaine), medicants, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance. Such materials contained in the vial 200 can be selectively delivered to a user's skin while the handpiece assembly 100 is being used. In some embodiments, the handpiece assembly 100 includes an adjustable valve or other flow control feature to enable a user to regulate the rate of delivery of such fluids or other materials to the treatment surface.
In some embodiments, one or more materials can be strategically embedded, impregnated, placed, stored and/or otherwise disposed on one or more surfaces or areas of the tip or other portion or component of the skin treatment system. Such materials can comprise solids, semi-solids, other dried substances, gels, concentrated solutions and/or the like. For example, such materials can be provided in loose form (e.g., positioned on or within a recess, other portion of the tip, within a cartridge or other container, adhered to one or more surfaces, etc.), as a tablet, capsule, pill, disc or other dissolvable solid, saturated within a foam pad or other sponge-like material and/or the like. Thus, in certain arrangements, water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants and/or other fluids which are delivered to the tip can selectively dissolve, liquefy, melt, soften, dilute or otherwise prepare the materials embedded, impregnated and/or otherwise positioned on the tip, within a cartridge or other container and/or on or within another portion or component of a skin treatment system (e.g., handpiece assembly, fluid line upstream of the handpiece assembly, etc.). Accordingly, the desired human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, peptides, amino acids, UVA and/or UVB sunblocks, other sunblocking agents, skin tightening agents, hyaluronic acid (HA), other hydration agents, hair removal or hair growth suppression agents, medicaments and pharmaceuticals, water, saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, skin brightening or lightening agents, other acids, anesthetics, medicants, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance can be advantageously provided to the skin surface being treated, as desired or required.
In addition, as illustrated in
With continued reference to
In other arrangements, two or more different cartridges 200 can be used during a skin treatment procedure. For example, a particular procedure may require the contents (e.g., serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, proteins, brightening or lightening agents, peptides, other fluids or substances, etc.) of two or more different cartridges 200. Thus, a user can load and/or unload a combination of cartridges 200 or other containers within a handpiece assembly 100 during a treatment procedure, either at the same time or sequentially (e.g., one after another).
According to some embodiments, as illustrated in
In such embodiments, the internal volume of the cartridge or vial containing the fluid and/or other material to be selectively delivered to the handpiece assembly can be reduced as fluid and/or other material is expelled from the cartridge. This can help ensure that the internal portion of the cartridge that contains the serum, other liquid and/or other material to be delivered to the handpiece assembly does not include air or other gases. Thus, the treatment media can be consistently and reliably maintained at the distal end of the cartridge interior (e.g., toward the cartridge outlet) during a treatment procedure, regardless if and how a user tilts or otherwise maneuvers the handpiece assembly.
The vial or cartridge 200 can include a main cylindrical portion and a nozzle portion. In some arrangements, the nozzle portion comprises a septum, membrane or other member that can be pierced, punctured or otherwise compromised to access the interior contents of the vial 200 (e.g., serum, other liquids or materials, etc.). The septum can include one or more flexible, rigid and/or semi-rigid materials, such as, for example, rubber, plastic, paper and/or the like.
In some embodiments, a vial or other fluid container 200 can be sized, shaped and otherwise configured to snugly or generally snugly fit within the main body portion 110 of the handpiece assembly 100. Therefore, in some arrangements, the vial or cartridge 200 is secured to the handpiece assembly 100 by friction or by the generally tight tolerances of the recess of the handpiece assembly.
As noted above, the waste conduit 180 (e.g., flexible tubing, hose, etc.) to which the handpiece assembly 100 connects is in fluid communication with a vacuum or other suction source (e.g., pump, other fluid transfer device, etc.). Thus, exfoliated skin, spent fluids and/or other waste materials can be transported away from the tip 130 to a canister (not shown) or other waste source. The rate of transfer of such waste materials can depend on one or more factors, such as, for example, the setting of the vacuum or suction source, the characteristics (e.g., diameter, length, smoothness, etc.) of the various conduits or channels through which the waste materials are conveyed, the viscosity, density and other fluid properties of the waste materials and/or the like.
As discussed herein, in some embodiments, the flow of serums, other fluids and/or any other materials from a vial or cartridge 200 or other source through the handpiece assembly 100 can be regulated by the user using one or more valves or other flow control devices or features.
In some embodiments, a vacuum in fluid communication with the waste conduit 180 can be configured to remove waste materials from the tip 130 and help deliver serums, other fluids and/or any other materials from the vial or cartridge 200 to the tip 130. When the tip 130 is positioned against the subject's skin, suction created by the vacuum source can be transmitted to one or more fluid channel or conduits of the handpiece assembly 100. Such a suction force created within the corresponding channels or conduits of the handpiece assembly remains intact as long as the tip 130 is maintained against or substantially against the subject's skin. Consequently, the suction force crated by the vacuum source can be transferred to one or more fluid delivery channels of the assembly 100, thereby transferring fluids and/or other materials from the vial or other container toward the tip 130.
In some embodiments, serums, other fluids and/or other materials can be delivered to the tip 130 (e.g., from a cartridge, an external source, etc.) through one or more peripheral or other non-centrally located channels, conduits and/or other lines or fittings. For instance, in the handpiece assembly 100 illustrated in
According to certain embodiments, as illustrated in
According to certain embodiments, one or more of the fluid lines fluid conduits of the manifold system illustrated in
As discussed, the vials, cartridges, bottles (e.g., used in towers or other manifold-systems) and/or other fluid sources can include any combination of serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, human growth factors, cytokines, collagen, brightening or lightening agents, peptides, peeling agents, acids, antioxidants, matrix proteins, saline, water (e.g., distilled, tap water, filtered, etc.) and/or other liquids or substances, as desired or required by a particular application or use. In certain embodiments, a treatment protocol may require the use of one, two or more different cartridges for a specific procedure. Thus, vials or cartridges 200 can be removed from or inserted into a handpiece assembly prior to or during a particular procedure. Alternatively, when a manifold system is being used to supply fluids to the handpiece assembly, one or more valves can be actuated (e.g., manually or automatically) to enable the desired fluid and/or other substance to be in fluid communication with the handpiece assembly.
In any of the embodiments disclosed herein, a cartridge or vial 200 or a separate bottle contained within a manifold system can advantageously permit a user to deliver human growth factors, cytokines, soluble collagen, antioxidants, matrix proteins, serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, water (e.g., distilled, tap water, filtered, etc.), saline, other dilutants or dissolvents, vitamins, chemical exfoliation agents, lotions, soothing agents, brightening or lightening agents, peptides, peeling agents, acids, anesthetics, medicants, other non-active or active compounds, other fluids or materials, combination or mixtures thereof and/or any other substance to a handpiece assembly from one or more external fluid sources. For example, in some embodiments, the conduit 450 can be placed in fluid communication with one or more containers. Such containers can comprise the desired serums, salicylic acid, other anti-acne acids and materials, microcapsules, capsules, other time-release products and substances, human growth factors, cytokines, collagen, antioxidants, matrix proteins, brightening or lightening agents, peptides, peeling agents, acids, medicants, other fluids or substances, combinations thereof and/or the like, as desired or required by a particular treatment. Thus, the handpiece assembly 100 (e.g., the vial or container 200 of the handpiece assembly) can be used as an interface between the handpiece assembly and a relatively larger source of treatment media. For example, a handpiece assembly 100 can be advantageously placed in fluid communication with a multi-container system such as the one disclosed in U.S. patent application Ser. No. 11/392,348, filed on March 29, 2006 and published on Jul. 5, 2007 as U.S. Publication 2007/0156124, the entirety of which is hereby incorporated by reference herein.
According to certain arrangements, a cartridge 400 includes one or more solids, granular materials, gels, concentrated fluids and/or other substances that are adapted to dissolve, dilute, soften or otherwise mix when contacted by water, saline, other dilutants or dissolvents and/or other fluids. Thus, such materials or other substances can be placed within the cartridge 400 in one or more forms, such as, for example, as powder, granular material, a tablet, a capsule, a pill, other dissolvable solid, a concentrated solution, a gel and/or the like. In other embodiments, such solids, gels and/or other materials can be situated on the tip or other portion of the system (e.g., within a post or recess, adhered to one or more other exposed or hidden surfaces, within a removable cartridge upstream of the handpiece assembly, etc.), impregnated into a foam pad or other member and/or at any other location. Regardless of their exact composition, location and/or other details, such materials and/or other substances can be configured to dissolve, dilute and/or otherwise mix with water, saline and/or other fluids being conveyed through the handpiece assembly 100.
According to some embodiments, the effectiveness of performing a microdermabrasion procedure can be improved by the delivery of energy, light or air (or other fluid), the delivery of mechanical energy (e.g., acoustic energy, needle penetrations, etc.), the transfer of heat (e.g., to and/or from the skin) and/or the like. This can be conducted concurrently with a microdermabrasion procedure and/or before or after a microdermabrasion as desired or required. In some embodiments, for example, the delivery of energy (e.g., radiofrequency or RF, ultrasound, microwave, etc.), laser, light and/or the like to the skin surface can assist with one or more aspects of the skin treatment process (e.g., its effectiveness, the final result, etc.), healing and recovery. For example, in some embodiments, the application of such ancillary treatments or modalities can improve skin texture and look. In some embodiments, recovery time following a microdermabrasion procedure can be reduced. The application of such treatments or items can also assist with the penetration of the various serums, other liquids and/or other substances used in connection with a skin treatment procedure (e.g., via fluid delivery from a vial or manifold to the tip of the handpiece assembly). The application of energy, mechanical disruption, transfer of heat to or from the skin and/or any other ancillary steps or processes can be used when the microdermabrasion system is being used with or without concurrent (e.g., continuous or intermittent) fluid delivery.
In some embodiments, a handpiece assembly and/or another aspect of a microdermabrasion system is configured to selectively deliver energy, heat (e.g., to or from the skin), air or other fluid, mechanical disruption, light and/or the like to the subject's skin. For example, a handpiece assembly can comprise one or more radiofrequency (RF) electrodes, ultrasound transducers, light, laser or microwave emitters and/or the like. Further, as discussed in greater detail herein with reference to
In other embodiments, however, the delivery of such energy and/or other items is performed using a separate device or system (e.g., a dedicated energy emitter unit, etc.).
In some embodiments, it may be beneficial to provide air or other fluid to the skin surface being treated. The air can be delivered at a particular flowrate, pressure, intensity, pulsing rate or frequency and/or time duration to help achieve a particular effect on the skin surface. For example, air or other fluid can be pulsed onto the skin during, before and/or after a microdermabrasion procedure to promote and facilitate the transfer of serums, other liquids and/or other materials at least partially into the subject's skin tissue after exfoliation. In some embodiments, air pulsing can comprise square wave pulsing (e.g., having sequential air delivery and no air delivery phases, one after another, etc.).
With continued reference to
In some embodiments, the handpiece assembly 100A can include one or more air delivery passages 124A that are configured to continuously or intermittently deliver air and/or other fluid to the tip 130A. As illustrated in
If, during use, the vacuum source is activated and peripheral lip 132A of the tip 130A is in contact with the subject's skin, the suction passage 126A can create a negative pressure along the distal tip (e.g., along the interior of the peripheral lip), thereby drawing one or more treatment serums or fluids to the tip 130A (e.g., via the fluid delivery passage 122A). Further, in some embodiments, the application of a negative pressure along the tip 130A of the assembly 100A can help draw the subject's skin in contact with the interior lip or ridge 128A. Consequently, only the region along the tip between the peripheral lip 132A and the interior lip 128A may be subjected to the suction created by the vacuum source. Thus, air can be selectively transferred through the air delivery passage 124A of the assembly and onto a subject's skin without losing negative pressure along the annular region of the tip defined by the peripheral and inner lips 132A, 128A. This can advantageously permit the delivery of air to the skin of the subject during a “wet” microdermabrasion process (e.g., one in which treatment fluids are delivered to the working end of the device).
In some embodiments, air is delivered through the air delivery passage 124A in individual puffs. Accordingly, depending on their volume, intensity, pressure and/or other properties, such puffs can help exert an intermittent force along the subject's skin. As noted above, such mechanical or pneumatic agitation of the skin can provide one or more benefits. For example, the resulting force or pressure on the skin can help drive serums, liquids and/or other substances being delivered to the tip (e.g., via the fluid delivery passage) deeper into the skin tissue. The repetitive agitation created by the air puffs can also help loosen dirt, oils and/or other unwanted materials from the pores along the skin surface being treated.
The handpiece assembly 100A can be configured to allow a user to adjust the manner in which air is delivered through the air delivery passage 124 and/or the amount of negative pressure that is applied by the vacuum source through the suction passage 126A (e.g., or the amount negative pressure that is realized along the tip 130A). In some embodiments, the negative pressure within the suction passage 126A is sufficiently high to maintain contact between the subject's skin and the peripheral and inner lips 132A, 128A of the tip 130A during use. This can help maintain a steady and consistent flow of treatment fluids to the working surface while a skin surface is exfoliated or otherwise treated. A sufficiently high vacuum along the tip can also help ensure that the lips 132A, 128A will not lose contact with the skin surface as air is delivered (e.g. in puffs) to the skin surface.
According to some embodiments, one or more needles or other piercing members can be used to agitate and/or penetrate certain areas or regions of the subject's skin, before, during or following a microdermabrasion or other skin treatment procedure. The needles or other penetrating members can be moved in and out of adjacent skin tissue over a period of time. Consequently, a plurality of the small diameter passages can be created in the targeted skin tissue, at least temporarily. Such passages can allow serums, other treatment agents and/or other substances that are delivered or otherwise applied to the skin to be advantageously carried deeper into the skin tissue. Additional details regarding the use of needles in connection with skin treatment procedures are found in a provisional application being filed concurrently herewith and titled, “SKIN TREATMENT SYSTEMS AND METHODS USING NEEDLES,” the entirety of which is hereby incorporated by reference herein.
In other embodiments, one or more ultrasonic transducers can be positioned relative to the subject's skin before, during and/or after a microdermabrasion procedure so as to selectively deliver acoustic energy to the skin. In some embodiments, the transducers are configured to deliver a relatively low amount of energy to the subject in order to at least partially agitate (e.g., mechanically) the targeted skin tissue. The delivery of ultrasonic energy to the skin may, in certain circumstances, cause the skin tissue to heat.
As with other energy sources disclosed herein, ultrasonic energy can be delivered by a handpiece assembly that comprises one or more transducers. However, in other embodiments, a separate device or component is used to deliver a desired amount of ultrasonic energy to or near the skin tissue.
In other embodiments, the handpiece assembly and/or a separate (e.g., non-integrated) device or system is configured to selectively deliver energy to the targeted skin tissue of the subject. For example, the types of energy-based modalities that can be directed to the skin surface include radiofrequency (RF), microwave, ultrasound and/or the like. As noted above, such energy delivery can be performed before, during and/or after a microdermabrasion or other skin treatment procedure. In some embodiments, the application of such energy to the skin can provide one or more anatomical responses and/or benefits. For example, if the energy applied to the skin is sufficiently high, the skin tissue can be at least partially heated. Such heating and/or other physiological (e.g., biochemical, biological, chemical, etc.) response or effect can, in some embodiments, facilitate the passage of serums and/or other treatment fluids at least partially within the skin tissue.
In some embodiments, one or more forms of light can be applied to the skin of the subject, before, during or after a microdermabrasion or other skin treatment procedure. The type of light, its intensity, power, frequency, wavelength, duration of exposure and/or other properties can vary, as desired or required for a particular application or use. In some embodiments, one or more properties of the light source can be varied, during a procedure and/or between procedures. In some embodiments, as illustrated in
In some embodiments, two or more different types of light sources can be provided as options for the subject or the user performing a procedure on the subject. For example, with reference back to
One or more light sources can be incorporated directly or indirectly into the handpiece assembly that is configured to perform microdermabrasion. For example, an annular light can be positioned along or near (or embedded partially within) the lip at the distal tip of a microdermabrasion handheld assembly. In other embodiments, the light can be removably mounted along an outside surface of the assembly.
In some embodiments, the use of light is configured to chemically or biochemically “activate” one or more treatment fluids and/or other substances have been or are being delivered to the skin surface of the subject. The activation of certain substances can provide one or more therapeutic or otherwise beneficial results. In other embodiments, the use of red, blue and/or other light can provide one or more direct benefits to the targeted skin tissue. In some embodiments, for example, red light therapy can be used to complement other skin care treatments, while blue light treatment can improve the general appearance of oily and/or acne-prone skin.
In some embodiments, light can be used to heat and/or at least partially modify or affect (e.g., at the cellular level) skin and adjacent tissue of the subject. For example, heat-producing or heat-inducing light source can be directed at the skin for a specific time period, before, during or after a skin treatment procedure (e.g., microdermabrasion). Light sources can include bulbs (e.g., incandescent, fluorescent, low-pressure sodium, high-intensity discharge, etc.), lasers and/or the like. As discussed in greater detail below, heating of the skin can provide one or more benefits to the subject. For example, heating of skin tissue can enable the pores of the subject to open or dilate (e.g., allowing serums and/or other treatment fluids or substances to penetrate deeper into the skin surface). Heating of the skin can also increase blood circulation in the adjacent vessels (e.g., to help improve healing and recovery following a treatment procedure).
Exposing the skin to hot and/or cold temperature can assist with various aspects associated with microdermabrasion and other skin treatment techniques and procedures. For example, as discussed herein, heating skin can open the skin's pores, thereby allowing serums, other treatment fluids or materials and/or the like to enhance penetration and migration of such materials into the skin. Further, cooling the skin can cause pores to close, at least partially, allowing therapeutic fluids and/or other materials that previously entered the pores to stay within the skin for a longer time period.
In some embodiments, one or more devices (e.g., handheld devices) can be used to conductively cool and/or heat skin, before, during and/or after a skin treatment procedure (e.g., microdermabrasion). One embodiment of such a heating and cooling system is illustrated in
With continued reference to
In some embodiments, the station comprises one or more thermally conductive materials, such as, for example, aluminum, copper, other metal or alloys. As illustrated in
When the thermoelectric devices and/or other heating and/or cooling devices of the station are activated, the wells of the station can be heated or cooled, in accordance with the desired thermal conditioning effect of that station 510. In some embodiments, if thermoelectric devices are used to heat or cool the station 510, an additional station (not shown) can be positioned on the opposite surface of the thermoelectric device so that the additional station also undergoes heating or cooling (e.g., the opposite thermal effect of the main station).
One embodiment of a thermal conditioning handheld assembly 600 is illustrated in
As illustrated in
With continued reference to
Another embodiment of a thermal handheld assembly is illustrated in
Regardless of their exact shape, size, configuration and/or other properties, the thermal handheld assemblies 600, 600A can be used to selectively heat or cool a subject's skin surface. As noted above, in one embodiment, the surface to be abraded (e.g., using microdermabrasion) can first be heated to open the skin pores and/or provide one or more other benefits. With the pores open, a microdermabrasion process can be performed. Accordingly, any serums, other treatment fluids and/or other substances that are delivered to the working end of the microdermabrasion device (e.g., along the skin surface that was previously heated, for example), could pass deeper and/or with greater ease into the open pores of the skin. Following the microdermabrasion process, the user can use a cold thermal conditioning assembly 600, 600A to cool the skin surface that was treated. As a result of cooling the skin surface, the pores of the skin can at least partially close, thereby trapping the potentially beneficial serums and/or other components within the skin. Such a treatment method can provide for a quicker recovery time, fewer complications and/or one or more other benefits or advantages.
As noted above, in some embodiments, the thermal conditioning handheld assemblies 600, 600A are configured to create a negative pressure or vacuum along the one or more openings 632, 632A at the assembly head 630, 630A. As illustrated in
According to some embodiments, the level of heating or cooling of the thermal assemblies 600 can be adjusted and controlled (e.g., by modifying the duty cycle of the thermoelectric devices or any other heating or cooling device that is thermally conditioning the station 510). In some embodiments, a thermostat and/or other temperature detection is used to ensure that the operating temperature of the station 510 and the handheld assemblies that the station is configured to heat do not reach dangerous or uncomfortable extremes.
In other embodiments, a skin surface can be heated or cooled using any other method or device. For example, skin can be heated using any of the energy or other modalities discussed herein (e.g., RF, ultrasound, microwave, etc.). In one embodiment, the liquids, serums and/or other treatment fluids delivered to the tip of a microdermabrasion device (e.g., from a vial or cartridge, a bottle of a manifold or tower system, etc.) can be heated or cooled before it reaches the skin surface. Therefore, one or more heating or cooling devices can be incorporated into the microdermabrasion handheld device or the fluid system that is coupled to the handheld device.
According to some embodiments, as discussed above with reference to the schematic of
With continued reference to
With continued reference to
One embodiment of a bottle 1010 configured for placement into the manifold system 1000 is illustrated in
In some embodiments, the various bottles or other containers 1010 positioned within a manifold system 1000 and/or vials or cartridges 1300 positioned within a recess of the handheld assembly can comprise an automatic identification tag 1150A, 1150B, 1350A, 1350B, such as, for example, a RFID chip, a barcode, etc. Such tags can be used to advantageously store information regarding the specific bottle, vial or other container. For example, the tag can include information regarding the contents of the container, expiration date, manufacturing date, size, lot number, skin procedure with which the contents are intended to be used, other limitations or restrictions on use (e.g., counter-indications, adverse effects, other fluids with which the contents should not be combined, etc.).
The RFID chip or other identifier can be read or otherwise detected (e.g., automatically, manually, etc.) by one or more readers or detectors of a manifold system 1000, a handheld assembly 100 and/or any other portion of a skin treatment system. For example, in some embodiments, such a reader can be placed at or near each station of a manifold system 1000 (e.g., adjacent the portion of the manifold to which the nozzle 1014 of the bottle 1010 secures). Accordingly, the RFID or other type of reader can detect and identify the RFID chip or other identifier of the bottle or other container Likewise, a RFID or other type of reader can detect and identify the RFID chip or other identifier 1350 of a vial 1300 when the vial 1300 is properly positioned within the handheld assembly.
Therefore, in circumstances where the detected identifier is inconsistent with the proper, safe, appropriate and/or approved operation of the system, the system can be configured to prevent fluid from that vial or container from being used (e.g., by terminating the vacuum source, by maintaining a solenoid valve or other valve in the closed position, etc.).
The use of the RFID chips or other identifiers on the bottles, vials and/or other containers of the system can provide one or more other advantages or benefits. The collection of data regarding use of the corresponding container (e.g., bottle, vial, etc.) can be collected to generate reports for billing, reordering and/or other purposes. In some embodiments, the number of times that a container can be removed and reinserted within a manifold or handheld assembly can be limited (e.g., 1, 2, 3, 4, etc.), as desired or required. For example, such limits can help prevent or reduce the likelihood of contamination of the fluid. In some embodiments, the automatic identification of the fluid container being secured to the system (e.g., manifold station, handheld assembly, etc.) can allow the system to determine if a rinse, flush and/or other preparatory steps are required before the fluid from that container can be used.
The systems, apparatuses, devices and/or other articles disclosed herein may be formed through any suitable means. The various methods and techniques described above provide a number of ways to carry out the invention. Of course, it is to be understood that not necessarily all objectives or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, those skilled in the art will recognize that the methods may be performed in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objectives or advantages as may be taught or suggested herein.
Furthermore, the skilled artisan will recognize the interchangeability of various features from different embodiments disclosed herein. Similarly, the various features and steps discussed above, as well as other known equivalents for each such feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Additionally, the methods which are described and illustrated herein are not limited to the exact sequence of acts described, nor are they necessarily limited to the practice of all of the acts set forth. Other sequences of events or acts, or less than all of the events, or simultaneous occurrence of the events, may be utilized in practicing the embodiments of the invention.
Although the invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and obvious modifications and equivalents thereof. Accordingly, it is not intended that the invention be limited, except as by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 15/430,209 filed Feb. 10, 2017, which is a continuation of U.S. patent application Ser. No. 14/211,290 filed Mar. 14, 2014, which claims the priority benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/791,157 filed Mar. 15, 2013, the entireties of all of which are hereby incorporated by reference herein. The entireties of U.S. patent application Ser. No. 12/346,582, filed Dec. 30, 2008 and issued on Jan. 1, 2013 as U.S. Pat. No. 8,343,116, and U.S. patent application Ser. No. 11/392,348, filed Mar. 29, 2006 and issued on Nov. 1, 2011 as U.S. Pat. No. 8,048,089, are hereby incorporated by reference herein and made a part of the present specification.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1651585 | Clair | Dec 1927 | A |
| 2608032 | Garver | Aug 1952 | A |
| 2631583 | Lavergne | Mar 1953 | A |
| 2701559 | Cooper | Feb 1955 | A |
| 2712823 | Kurtin | Jul 1955 | A |
| 2867214 | Wilson | Jan 1959 | A |
| 2881763 | Robbins | Apr 1959 | A |
| 2921585 | Schumann | Jan 1960 | A |
| 3037509 | Schutz | Jun 1962 | A |
| 3085573 | Meyer et al. | Apr 1963 | A |
| 3214869 | Stryker | Nov 1965 | A |
| 3468079 | Kaufman | Sep 1969 | A |
| 3476112 | Elstein | Nov 1969 | A |
| 3481677 | Abrahamson | Dec 1969 | A |
| 3505993 | Lewes et al. | Apr 1970 | A |
| 3560100 | Spatz | Feb 1971 | A |
| 3574239 | Sollerud | Apr 1971 | A |
| 3715838 | Young et al. | Feb 1973 | A |
| 3865352 | Nelson et al. | Feb 1975 | A |
| 3866264 | Engquist | Feb 1975 | A |
| 3930598 | Slagle | Jan 1976 | A |
| 3948265 | Al Ani | Apr 1976 | A |
| 3964212 | Karden | Jun 1976 | A |
| 3968789 | Simoncini | Jul 1976 | A |
| 3977084 | Sloan | Aug 1976 | A |
| 4121388 | Wilson | Oct 1978 | A |
| 4155721 | Fletcher | May 1979 | A |
| 4170821 | Booth | Oct 1979 | A |
| 4182329 | Smit et al. | Jan 1980 | A |
| 4203431 | Abura et al. | May 1980 | A |
| 4216233 | Stein | Aug 1980 | A |
| 4225254 | Holberg et al. | Sep 1980 | A |
| D260176 | Boschetti et al. | Aug 1981 | S |
| 4289158 | Nehring | Sep 1981 | A |
| 4299219 | Norris, Jr. | Nov 1981 | A |
| 4342522 | Mackles | Aug 1982 | A |
| 4378804 | Cortese | Apr 1983 | A |
| 4500222 | Clading-Boel | Feb 1985 | A |
| 4560373 | Sugino et al. | Dec 1985 | A |
| 4646480 | Williams | Mar 1987 | A |
| 4646482 | Chitjian | Mar 1987 | A |
| 4655743 | Hyde | Apr 1987 | A |
| 4676749 | Mabille | Jun 1987 | A |
| 4706676 | Peck | Nov 1987 | A |
| 4718467 | Di Gianfilippo et al. | Jan 1988 | A |
| 4754756 | Shelanski | Jul 1988 | A |
| 4757814 | Wang et al. | Jul 1988 | A |
| 4764362 | Barchas | Aug 1988 | A |
| 4795421 | Blasius, Jr. et al. | Jan 1989 | A |
| 4811734 | McGurk-Burleson et al. | Mar 1989 | A |
| 4836192 | Abbate | Jun 1989 | A |
| 4875287 | Creasy et al. | Oct 1989 | A |
| 4886078 | Shiftman | Dec 1989 | A |
| 4887994 | Bedford | Dec 1989 | A |
| 4900316 | Yamamoto | Feb 1990 | A |
| 4917086 | Feltovich et al. | Apr 1990 | A |
| 4925450 | Imonti et al. | May 1990 | A |
| 4940350 | Kim | Jul 1990 | A |
| 4957747 | Stiefel | Sep 1990 | A |
| 5006004 | Dirksing et al. | Apr 1991 | A |
| 5006339 | Bargery et al. | Apr 1991 | A |
| 5012797 | Clarke | May 1991 | A |
| 5035089 | Tillman et al. | Jul 1991 | A |
| 5037431 | Summers et al. | Aug 1991 | A |
| 5037432 | Molinari | Aug 1991 | A |
| 5054339 | Yacowitz | Oct 1991 | A |
| 5100412 | Rosso | Mar 1992 | A |
| 5100424 | Jang | Mar 1992 | A |
| 5119839 | Rudolph | Jun 1992 | A |
| 5122153 | Harrel | Jun 1992 | A |
| 5171215 | Flanagan | Dec 1992 | A |
| 5192269 | Poli et al. | Mar 1993 | A |
| 5207234 | Rosso | May 1993 | A |
| 5222956 | Waldron | Jun 1993 | A |
| 5242433 | Smith et al. | Sep 1993 | A |
| 5254109 | Smith et al. | Oct 1993 | A |
| 5368581 | Smith et al. | Nov 1994 | A |
| 5387215 | Fisher | Feb 1995 | A |
| 5391151 | Wilmot | Feb 1995 | A |
| 5417674 | Smith et al. | May 1995 | A |
| 5419772 | Teitz et al. | May 1995 | A |
| 5441490 | Svedman | Aug 1995 | A |
| 5460620 | Smith et al. | Oct 1995 | A |
| 5470323 | Smith et al. | Nov 1995 | A |
| 5484427 | Gibbons | Jan 1996 | A |
| 5490736 | Haber et al. | Feb 1996 | A |
| 5512044 | Duer | Apr 1996 | A |
| 5562642 | Smith et al. | Oct 1996 | A |
| 5562643 | Johnson | Oct 1996 | A |
| 5611687 | Wagner | Mar 1997 | A |
| 5612797 | Clarke | Mar 1997 | A |
| 5658583 | Zhang et al. | Aug 1997 | A |
| 5674235 | Parisi | Oct 1997 | A |
| 5676643 | Cann et al. | Oct 1997 | A |
| 5676648 | Henley | Oct 1997 | A |
| 5683971 | Rose et al. | Nov 1997 | A |
| 5697920 | Gibbons | Dec 1997 | A |
| 5707383 | Bays | Jan 1998 | A |
| 5713785 | Nishio | Feb 1998 | A |
| 5735833 | Olson | Apr 1998 | A |
| 5759185 | Grinberg | Jun 1998 | A |
| 5762640 | Kajiwara et al. | Jun 1998 | A |
| 5779519 | Oliver | Jul 1998 | A |
| 5800446 | Banuchi | Sep 1998 | A |
| 5807353 | Schmitz | Sep 1998 | A |
| 5810842 | Di Fiore et al. | Sep 1998 | A |
| 5813416 | Rudolph | Sep 1998 | A |
| 5817050 | Klein | Oct 1998 | A |
| 5834510 | Yu et al. | Nov 1998 | A |
| 5846215 | Zygmont | Dec 1998 | A |
| 5848998 | Marasco, Jr. | Dec 1998 | A |
| 5857995 | Thomas et al. | Jan 1999 | A |
| 5861142 | Schick | Jan 1999 | A |
| 5873881 | McEwen et al. | Feb 1999 | A |
| 5879323 | Henley | Mar 1999 | A |
| 5882201 | Salem | Mar 1999 | A |
| 5885260 | Mehl, Sr. et al. | Mar 1999 | A |
| 5908401 | Henley | Jun 1999 | A |
| 5919152 | Zygmont | Jul 1999 | A |
| 5919479 | Zhang et al. | Jul 1999 | A |
| 5954730 | Bernabei | Sep 1999 | A |
| 5971999 | Naldoni | Oct 1999 | A |
| 5980555 | Barbut et al. | Nov 1999 | A |
| 6019749 | Fields et al. | Feb 2000 | A |
| 6023639 | Hakky et al. | Feb 2000 | A |
| 6024733 | Eggers et al. | Feb 2000 | A |
| 6027402 | Oliver | Feb 2000 | A |
| 6039745 | Di Fiore et al. | Mar 2000 | A |
| 6042552 | Cornier | Mar 2000 | A |
| 6080165 | DeJacma | Jun 2000 | A |
| 6080166 | McEwen et al. | Jun 2000 | A |
| 6090085 | Mehl, Sr. et al. | Jul 2000 | A |
| 6120512 | Bernabei | Sep 2000 | A |
| 6129701 | Cimino | Oct 2000 | A |
| 6136008 | Becker et al. | Oct 2000 | A |
| 6139553 | Dotan | Oct 2000 | A |
| 6139554 | Karkar et al. | Oct 2000 | A |
| 6142155 | Rudolph | Nov 2000 | A |
| 6149634 | Bernabei | Nov 2000 | A |
| 6159226 | Kim | Dec 2000 | A |
| 6162218 | Elbrecht et al. | Dec 2000 | A |
| 6162232 | Shadduck | Dec 2000 | A |
| 6165059 | Parkin et al. | Dec 2000 | A |
| 6176198 | Kao et al. | Jan 2001 | B1 |
| 6183451 | Mehl, Sr. et al. | Feb 2001 | B1 |
| 6183483 | Chang | Feb 2001 | B1 |
| 6193589 | Khalaj | Feb 2001 | B1 |
| 6196982 | Ball | Mar 2001 | B1 |
| 6231593 | Meserol | May 2001 | B1 |
| 6235039 | Parkin et al. | May 2001 | B1 |
| 6238275 | Metcalf et al. | May 2001 | B1 |
| 6241739 | Waldron | Jun 2001 | B1 |
| 6245347 | Zhang et al. | Jun 2001 | B1 |
| 6264666 | Coleman et al. | Jul 2001 | B1 |
| 6277116 | Utely et al. | Aug 2001 | B1 |
| 6277128 | Muldner | Aug 2001 | B1 |
| 6283978 | Cheski et al. | Sep 2001 | B1 |
| 6284266 | Zhang et al. | Sep 2001 | B1 |
| 6299620 | Shadduck | Oct 2001 | B1 |
| 6306119 | Weber et al. | Oct 2001 | B1 |
| 6306147 | Bernabei et al. | Oct 2001 | B1 |
| 6322548 | Payne et al. | Nov 2001 | B1 |
| 6322568 | Bernabei et al. | Nov 2001 | B1 |
| 6332886 | Green et al. | Dec 2001 | B1 |
| 6355054 | Neuberger | Mar 2002 | B1 |
| 6368333 | Bernabei et al. | Apr 2002 | B2 |
| 6387103 | Shadduck | May 2002 | B2 |
| 6401289 | Herbert | Jun 2002 | B1 |
| 6409736 | Bernabei | Jun 2002 | B1 |
| 6410599 | Johnson | Jun 2002 | B1 |
| RE37796 | Henley | Jul 2002 | E |
| 6414032 | Johnson | Jul 2002 | B1 |
| 6420431 | Johnson | Jul 2002 | B1 |
| 6423078 | Bays et al. | Jul 2002 | B1 |
| 6423750 | Johnson | Jul 2002 | B1 |
| 6432113 | Parkin et al. | Aug 2002 | B1 |
| 6432114 | Rosso | Aug 2002 | B1 |
| 6471712 | Burres | Oct 2002 | B2 |
| 6477410 | Henley et al. | Nov 2002 | B1 |
| 6482212 | Bernabei et al. | Nov 2002 | B1 |
| 6488646 | Zygmont | Dec 2002 | B1 |
| 6494856 | Zygmont | Dec 2002 | B1 |
| 6500183 | Waldron | Dec 2002 | B1 |
| 6503256 | Parkin et al. | Jan 2003 | B2 |
| 6508813 | Altshuler | Jan 2003 | B1 |
| 6511486 | Mercier et al. | Jan 2003 | B2 |
| 6514262 | Di Fiore et al. | Feb 2003 | B1 |
| 6520931 | Suh | Feb 2003 | B2 |
| 6527783 | Ignon | Mar 2003 | B1 |
| 6535761 | Bernabei | Mar 2003 | B2 |
| 6537242 | Palmer | Mar 2003 | B1 |
| 6540757 | Hruska et al. | Apr 2003 | B1 |
| 6546281 | Zhang et al. | Apr 2003 | B1 |
| 6562013 | Marasco, Jr. | May 2003 | B1 |
| 6562050 | Owen | May 2003 | B1 |
| 6564093 | Ostrow et al. | May 2003 | B1 |
| 6565535 | Zaias et al. | May 2003 | B2 |
| 6582442 | Simon et al. | Jun 2003 | B2 |
| 6589218 | Garcia | Jul 2003 | B2 |
| 6592595 | Mallett et al. | Jul 2003 | B1 |
| 6626445 | Murphy et al. | Sep 2003 | B2 |
| 6629927 | Mesaros et al. | Oct 2003 | B1 |
| 6629983 | Ignon | Oct 2003 | B1 |
| 6635035 | Marasco et al. | Oct 2003 | B1 |
| 6641591 | Shadduck | Nov 2003 | B1 |
| 6645184 | Zelickson et al. | Nov 2003 | B1 |
| 6652888 | Rhoades | Nov 2003 | B2 |
| 6666874 | Heitzmann et al. | Dec 2003 | B2 |
| 6673081 | Tavger et al. | Jan 2004 | B1 |
| 6673082 | Mallett et al. | Jan 2004 | B2 |
| D486915 | Warschewske et al. | Feb 2004 | S |
| 6685853 | Angelopoulous et al. | Feb 2004 | B1 |
| 6687537 | Bernabei | Feb 2004 | B2 |
| 6689380 | Marchitto et al. | Feb 2004 | B1 |
| 6695853 | Karasiuk | Feb 2004 | B2 |
| 6726673 | Zhang et al. | Apr 2004 | B1 |
| 6735470 | Henley et al. | May 2004 | B2 |
| 6743211 | Prausnitz et al. | Jun 2004 | B1 |
| 6743215 | Bernabei | Jun 2004 | B2 |
| 6764493 | Weber et al. | Jul 2004 | B1 |
| 6780426 | Zhang et al. | Aug 2004 | B2 |
| D496101 | Davison | Sep 2004 | S |
| 6800083 | Hiblar et al. | Oct 2004 | B2 |
| 6800849 | Staats | Oct 2004 | B2 |
| 6869611 | Kligman et al. | Mar 2005 | B1 |
| 6905487 | Zimmerman | Jun 2005 | B2 |
| 6911031 | Muldner | Jun 2005 | B2 |
| 6926681 | Ramey et al. | Aug 2005 | B1 |
| 6938805 | Brincat | Sep 2005 | B2 |
| 6942649 | Ignon et al. | Sep 2005 | B2 |
| 6960206 | Keane | Nov 2005 | B2 |
| 6980448 | Foss et al. | Dec 2005 | B2 |
| 7001355 | Nunomura et al. | Feb 2006 | B2 |
| 7004933 | McDaniel | Feb 2006 | B2 |
| D517699 | Lansohn | Mar 2006 | S |
| 7044938 | La Bianco et al. | May 2006 | B2 |
| 7051907 | Brincat | May 2006 | B2 |
| 7052503 | Bernabei | May 2006 | B2 |
| D522360 | Caserta et al. | Jun 2006 | S |
| 7069073 | Henley et al. | Jun 2006 | B2 |
| 7070488 | Suissa et al. | Jul 2006 | B2 |
| 7083580 | Bernabei | Aug 2006 | B2 |
| 7087036 | Busby et al. | Aug 2006 | B2 |
| 7087063 | Carson et al. | Aug 2006 | B2 |
| 7094252 | Koop | Aug 2006 | B2 |
| 7115275 | Clarot et al. | Oct 2006 | B2 |
| 7135011 | Powers et al. | Nov 2006 | B2 |
| 7153311 | Chung | Dec 2006 | B2 |
| 7166086 | Haider et al. | Jan 2007 | B2 |
| 7172572 | Diamond et al. | Feb 2007 | B2 |
| 7197359 | Tokudome et al. | Mar 2007 | B1 |
| 7198623 | Fischer et al. | Apr 2007 | B2 |
| 7232444 | Chang | Jun 2007 | B2 |
| 7241208 | Suissa et al. | Jul 2007 | B2 |
| D553005 | Py et al. | Oct 2007 | S |
| 7276051 | Henley et al. | Oct 2007 | B1 |
| 7293930 | Chuang | Nov 2007 | B2 |
| 7314326 | Rosenberg | Jan 2008 | B2 |
| 7316657 | Kleinhenz et al. | Jan 2008 | B2 |
| 7316671 | Lastovich et al. | Jan 2008 | B2 |
| 7318828 | Revivo | Jan 2008 | B1 |
| 7320691 | Pilcher et al. | Jan 2008 | B2 |
| 7320801 | Kelly | Jan 2008 | B2 |
| 7354423 | Zelickson et al. | Apr 2008 | B2 |
| 7364565 | Freeman | Apr 2008 | B2 |
| 7384405 | Rhoades | Jun 2008 | B2 |
| 7422567 | Lastovich et al. | Sep 2008 | B2 |
| 7427273 | Mitsui | Sep 2008 | B2 |
| 7440798 | Redding, Jr. | Oct 2008 | B2 |
| 7458944 | Liste et al. | Dec 2008 | B2 |
| D584151 | Murphy | Jan 2009 | S |
| 7476205 | Erdmann | Jan 2009 | B2 |
| 7477938 | Sun et al. | Jan 2009 | B2 |
| 7482314 | Grimes et al. | Jan 2009 | B2 |
| 7485125 | Sjostrom | Feb 2009 | B2 |
| 7489989 | Sukhanov et al. | Feb 2009 | B2 |
| 7507228 | Sun et al. | Mar 2009 | B2 |
| 7582067 | Van Acker | Sep 2009 | B2 |
| 7597900 | Zimmer et al. | Oct 2009 | B2 |
| 7597901 | Clarot et al. | Oct 2009 | B2 |
| 7658742 | Karasiuk | Feb 2010 | B2 |
| 7678120 | Shadduck | Mar 2010 | B2 |
| 7744582 | Sadowski et al. | Jun 2010 | B2 |
| 7789886 | Shadduck | Sep 2010 | B2 |
| 7837695 | Hart et al. | Nov 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7901373 | Tavger | Mar 2011 | B2 |
| 7951156 | Karasiuk | May 2011 | B2 |
| 7993333 | Oral et al. | Aug 2011 | B2 |
| 8025669 | David et al. | Sep 2011 | B1 |
| RE42960 | Waldron | Nov 2011 | E |
| 8048089 | Ignon et al. | Nov 2011 | B2 |
| 8066716 | Shadduck | Nov 2011 | B2 |
| 8088085 | Thiebaut et al. | Jan 2012 | B2 |
| 8105295 | Blott et al. | Jan 2012 | B2 |
| 8128638 | Karasiuk et al. | Mar 2012 | B2 |
| D664254 | Yokoyama et al. | Jul 2012 | S |
| 8221437 | Waldron et al. | Jul 2012 | B2 |
| 8231292 | Rabe et al. | Jul 2012 | B2 |
| 8236008 | Boone, III et al. | Aug 2012 | B2 |
| 8277287 | Hart | Oct 2012 | B2 |
| 8337513 | Shadduck | Dec 2012 | B2 |
| 8343116 | Ignon et al. | Jan 2013 | B2 |
| D678783 | Wilcox et al. | Mar 2013 | S |
| 8475507 | Dewey et al. | Jul 2013 | B2 |
| 8478396 | Tsao et al. | Jul 2013 | B2 |
| 8535299 | Giovannoli | Sep 2013 | B2 |
| 8545489 | Giovannoli | Oct 2013 | B2 |
| 8562626 | Sabir et al. | Oct 2013 | B2 |
| 8573874 | Neuner | Nov 2013 | B2 |
| 8579916 | Cheney | Nov 2013 | B2 |
| 8721662 | Karasiuk | May 2014 | B2 |
| D709617 | Iliesco de Grimaldi et al. | Jul 2014 | S |
| 8814836 | Ignon et al. | Aug 2014 | B2 |
| 8858570 | Chang | Oct 2014 | B2 |
| 8939669 | Le et al. | Jan 2015 | B2 |
| D722172 | Amemiya et al. | Feb 2015 | S |
| 8945104 | Boone, III et al. | Feb 2015 | B2 |
| 9044582 | Chang et al. | Jun 2015 | B2 |
| 9050133 | Boone, III et al. | Jun 2015 | B1 |
| 9056193 | Ignon et al. | Jun 2015 | B2 |
| 9072533 | Liu et al. | Jul 2015 | B2 |
| D743558 | Kim et al. | Nov 2015 | S |
| 9186490 | Chang et al. | Nov 2015 | B2 |
| 9227044 | Bansal et al. | Jan 2016 | B2 |
| 9271755 | Luzon et al. | Mar 2016 | B2 |
| 9468464 | Shadduck | Oct 2016 | B2 |
| 9474886 | Ignon et al. | Oct 2016 | B2 |
| 9486615 | Ignon et al. | Nov 2016 | B2 |
| 9498610 | Ignon et al. | Nov 2016 | B2 |
| 9517085 | Karasiuk | Dec 2016 | B2 |
| 9550052 | Ignon et al. | Jan 2017 | B2 |
| 9566088 | Ignon et al. | Feb 2017 | B2 |
| 9597527 | Buchholz et al. | Mar 2017 | B2 |
| D787054 | Rini et al. | May 2017 | S |
| 9636521 | Isserow et al. | May 2017 | B2 |
| 9636522 | Oversluizen et al. | May 2017 | B2 |
| 9642997 | Ignon et al. | May 2017 | B2 |
| 9662482 | Ignon et al. | May 2017 | B2 |
| 9669233 | Quisenberry et al. | Jun 2017 | B2 |
| 9675817 | Isserow et al. | Jun 2017 | B2 |
| 9700684 | Vlodaver et al. | Jul 2017 | B2 |
| 9731053 | Alai | Aug 2017 | B2 |
| 9775645 | Boone, III | Oct 2017 | B2 |
| 9775646 | Shadduck | Oct 2017 | B2 |
| 9775976 | Grez | Oct 2017 | B2 |
| 9814485 | Pratt et al. | Nov 2017 | B2 |
| 9814647 | Ajiki | Nov 2017 | B2 |
| 9814868 | Ignon et al. | Nov 2017 | B2 |
| 9833261 | Boone, III et al. | Dec 2017 | B2 |
| 9861442 | Tankovich et al. | Jan 2018 | B2 |
| D811381 | Morohoshi et al. | Feb 2018 | S |
| 9918727 | Boone, III et al. | Mar 2018 | B1 |
| 9949552 | Rabe et al. | Apr 2018 | B2 |
| 9950147 | Mehta | Apr 2018 | B2 |
| 9955769 | Rabe et al. | May 2018 | B2 |
| 9968800 | Anderson et al. | May 2018 | B2 |
| 10004919 | Lemmens et al. | Jun 2018 | B2 |
| D822845 | Shimobayashi et al. | Jul 2018 | S |
| 10010445 | Isserow et al. | Jul 2018 | B2 |
| 10022289 | Ajiki et al. | Jul 2018 | B2 |
| 10035007 | Ignon et al. | Jul 2018 | B2 |
| D825763 | Lim et al. | Aug 2018 | S |
| 10052467 | Bansal et al. | Aug 2018 | B2 |
| 10076354 | Knowlton | Sep 2018 | B2 |
| 10076646 | Casasanta, III et al. | Sep 2018 | B2 |
| 10080581 | Knowlton | Sep 2018 | B2 |
| 10092478 | Amit | Oct 2018 | B1 |
| 10130390 | Hart et al. | Nov 2018 | B1 |
| 10130827 | Buchholz et al. | Nov 2018 | B2 |
| D836781 | Meurer et al. | Dec 2018 | S |
| 10172644 | Ignon et al. | Jan 2019 | B2 |
| 10179229 | Ignon et al. | Jan 2019 | B2 |
| 10188193 | Rabe et al. | Jan 2019 | B2 |
| 10206743 | Tankovich et al. | Feb 2019 | B2 |
| 10207034 | Collins | Feb 2019 | B2 |
| 10220122 | Clark, III et al. | Mar 2019 | B2 |
| 10238812 | Ignon | Mar 2019 | B2 |
| 10251675 | Ignon et al. | Apr 2019 | B2 |
| 10272258 | Quisenberry et al. | Apr 2019 | B2 |
| D851759 | Jones et al. | Jun 2019 | S |
| 10308378 | Goodwin et al. | Jun 2019 | B2 |
| 10314378 | Rabe et al. | Jun 2019 | B2 |
| 10321948 | Knowlton | Jun 2019 | B2 |
| D852962 | Chang | Jul 2019 | S |
| 10335191 | Knowlton | Jul 2019 | B2 |
| 10357641 | Ignon et al. | Jul 2019 | B2 |
| 10357642 | Ignon et al. | Jul 2019 | B2 |
| 10334933 | Rosario et al. | Aug 2019 | B2 |
| 10369073 | Rosario et al. | Aug 2019 | B2 |
| D861913 | Stamm et al. | Oct 2019 | S |
| 10456321 | Shadduck | Oct 2019 | B2 |
| 10456567 | Streeter | Oct 2019 | B2 |
| D867587 | Holtz | Nov 2019 | S |
| 10485983 | Boone, III et al. | Nov 2019 | B1 |
| D868981 | Salamon et al. | Dec 2019 | S |
| D873430 | Accolla | Jan 2020 | S |
| 10524835 | Shadduck et al. | Jan 2020 | B2 |
| 10556096 | Ignon et al. | Feb 2020 | B2 |
| 10556097 | Ignon et al. | Feb 2020 | B2 |
| 10583037 | Isserow et al. | Mar 2020 | B2 |
| D887571 | Liu | Jun 2020 | S |
| 10667985 | Decaux et al. | Jun 2020 | B2 |
| 10716924 | Knowlton | Jul 2020 | B2 |
| D893024 | Whiteside | Aug 2020 | S |
| 10737080 | Patterson | Aug 2020 | B2 |
| 10758261 | Richardson | Sep 2020 | B2 |
| 10772658 | Knowlton | Sep 2020 | B2 |
| 10792382 | Rafko | Oct 2020 | B2 |
| 10835287 | Shadduck et al. | Nov 2020 | B2 |
| 10856900 | Knowlton | Dec 2020 | B2 |
| 10874579 | Rembert | Dec 2020 | B1 |
| 10912428 | Daffer | Feb 2021 | B2 |
| 10918190 | Laudati | Feb 2021 | B2 |
| 10946191 | Cazares Delgadillo | Mar 2021 | B2 |
| 10952907 | Carver | Mar 2021 | B1 |
| 10993743 | Ignon et al. | May 2021 | B2 |
| 11020577 | Ignon et al. | Jun 2021 | B2 |
| 11045661 | Oversluizen et al. | Jun 2021 | B2 |
| D927008 | Rappaport | Aug 2021 | S |
| D928977 | Dijkstra | Aug 2021 | S |
| 11141761 | Connelly et al. | Oct 2021 | B2 |
| 11154723 | Lee | Oct 2021 | B2 |
| 11202657 | Ignon et al. | Dec 2021 | B2 |
| 11213321 | Ignon et al. | Jan 2022 | B2 |
| 11224728 | Ignon et al. | Jan 2022 | B2 |
| 11241357 | Ignon et al. | Feb 2022 | B2 |
| 11291474 | Nicolas et al. | Apr 2022 | B2 |
| 11351063 | Locke et al. | Jun 2022 | B2 |
| 11446477 | Ignon | Sep 2022 | B2 |
| 11452852 | Quan et al. | Sep 2022 | B2 |
| 11504148 | Friend | Nov 2022 | B2 |
| 11517350 | Ignon et al. | Dec 2022 | B2 |
| 11547840 | Ignon et al. | Jan 2023 | B2 |
| 20010023351 | Eilers | Sep 2001 | A1 |
| 20010049511 | Coleman et al. | Dec 2001 | A1 |
| 20020016601 | Shadduck | Feb 2002 | A1 |
| 20020041891 | Cheski | Apr 2002 | A1 |
| 20020058952 | Weber et al. | May 2002 | A1 |
| 20020099356 | Unger et al. | Jul 2002 | A1 |
| 20020107527 | Burres | Aug 2002 | A1 |
| 20020128663 | Mercier et al. | Sep 2002 | A1 |
| 20020133110 | Citow | Sep 2002 | A1 |
| 20020133176 | Parkin et al. | Sep 2002 | A1 |
| 20020151826 | Ramey et al. | Oct 2002 | A1 |
| 20020151908 | Mallett et al. | Oct 2002 | A1 |
| 20020162863 | Brincat | Nov 2002 | A1 |
| 20020188261 | Hruska | Dec 2002 | A1 |
| 20020198488 | Yao | Dec 2002 | A1 |
| 20030012415 | Cossel | Jan 2003 | A1 |
| 20030018252 | Duchon et al. | Jan 2003 | A1 |
| 20030060834 | Muldner | Mar 2003 | A1 |
| 20030093040 | Mikszta et al. | May 2003 | A1 |
| 20030093089 | Greenberg | May 2003 | A1 |
| 20030097139 | Karasiuk | May 2003 | A1 |
| 20030167032 | Ignon | Sep 2003 | A1 |
| 20030187462 | Chang | Oct 2003 | A1 |
| 20030208159 | Ignon | Nov 2003 | A1 |
| 20030212127 | Glassman et al. | Nov 2003 | A1 |
| 20030212415 | Karasiuk | Nov 2003 | A1 |
| 20040010222 | Nunomura et al. | Jan 2004 | A1 |
| 20040010269 | Grimes et al. | Jan 2004 | A1 |
| 20040015139 | La Bianco | Jan 2004 | A1 |
| 20040087972 | Mulholland et al. | May 2004 | A1 |
| 20040092895 | Harmon | May 2004 | A1 |
| 20040092959 | Bernaz | May 2004 | A1 |
| 20040097967 | Ignon | May 2004 | A1 |
| 20040122447 | Harmon et al. | Jun 2004 | A1 |
| 20040127914 | Chung | Jul 2004 | A1 |
| 20040138680 | Twitchell et al. | Jul 2004 | A1 |
| 20040143274 | Shadduck | Jul 2004 | A1 |
| 20040162565 | Carson et al. | Aug 2004 | A1 |
| 20040166172 | Rosati et al. | Aug 2004 | A1 |
| 20040210280 | Liedtke | Oct 2004 | A1 |
| 20040219179 | McDaniel | Nov 2004 | A1 |
| 20040229295 | Marchitto et al. | Nov 2004 | A1 |
| 20040236291 | Zelickson et al. | Nov 2004 | A1 |
| 20040236375 | Redding, Jr. | Nov 2004 | A1 |
| 20040243149 | Lee, Jr. | Dec 2004 | A1 |
| 20040254587 | Park | Dec 2004 | A1 |
| 20040267285 | Chang | Dec 2004 | A1 |
| 20050037034 | Rhoades | Feb 2005 | A1 |
| 20050038377 | Redding, Jr. | Feb 2005 | A1 |
| 20050038448 | Chung | Feb 2005 | A1 |
| 20050059940 | Weber et al. | Mar 2005 | A1 |
| 20050065461 | Redding, Jr. | Mar 2005 | A1 |
| 20050070977 | Molina | Mar 2005 | A1 |
| 20050075599 | Redding, Jr. | Apr 2005 | A1 |
| 20050080465 | Zelickson et al. | Apr 2005 | A1 |
| 20050084509 | Bernstein | Apr 2005 | A1 |
| 20050148958 | Rucinski | Jul 2005 | A1 |
| 20050203111 | David | Sep 2005 | A1 |
| 20050209611 | Greenberg | Sep 2005 | A1 |
| 20050283176 | Law | Dec 2005 | A1 |
| 20060002960 | Zoeteweij et al. | Jan 2006 | A1 |
| 20060015059 | Redding, Jr. | Jan 2006 | A1 |
| 20060058714 | Rhoades | Mar 2006 | A1 |
| 20060100567 | Marchitto et al. | May 2006 | A1 |
| 20060116674 | Goble et al. | Jun 2006 | A1 |
| 20060161178 | Lee | Jul 2006 | A1 |
| 20060189964 | Anderson | Aug 2006 | A1 |
| 20060191562 | Numomura | Aug 2006 | A1 |
| 20060200099 | La Bianco et al. | Sep 2006 | A1 |
| 20060200172 | Shadduck | Sep 2006 | A1 |
| 20060200173 | Shadduck | Sep 2006 | A1 |
| 20060212025 | McDaniel | Sep 2006 | A1 |
| 20060212029 | Villacampa et al. | Sep 2006 | A1 |
| 20060222445 | Chuang | Oct 2006 | A1 |
| 20060253078 | Wu et al. | Nov 2006 | A1 |
| 20060253079 | McDonough et al. | Nov 2006 | A1 |
| 20060253125 | Ignon | Nov 2006 | A1 |
| 20060264893 | Sage, Jr. et al. | Nov 2006 | A1 |
| 20060264926 | Kochamba | Nov 2006 | A1 |
| 20060269580 | Cole et al. | Nov 2006 | A1 |
| 20060278661 | Cooper et al. | Dec 2006 | A1 |
| 20070005078 | Hart et al. | Jan 2007 | A1 |
| 20070020321 | Redding et al. | Jan 2007 | A1 |
| 20070043382 | Cheney | Feb 2007 | A1 |
| 20070049901 | Wu et al. | Mar 2007 | A1 |
| 20070065515 | Key | Mar 2007 | A1 |
| 20070073327 | Giovannoli | Mar 2007 | A1 |
| 20070088371 | Karasiuk | Apr 2007 | A1 |
| 20070093694 | Fassuliotis et al. | Apr 2007 | A1 |
| 20070123808 | Rhoades | May 2007 | A1 |
| 20070139630 | Kleman et al. | Jun 2007 | A1 |
| 20070149991 | Mulholland | Jun 2007 | A1 |
| 20070154502 | Hattendorf et al. | Jul 2007 | A1 |
| 20070156124 | Ignon | Jul 2007 | A1 |
| 20070178121 | First et al. | Aug 2007 | A1 |
| 20070198031 | Kellogg | Aug 2007 | A1 |
| 20070208353 | Shadduck | Sep 2007 | A1 |
| 20070239173 | Khalaj | Oct 2007 | A1 |
| 20070270738 | Wu et al. | Nov 2007 | A1 |
| 20080009802 | Lambino et al. | Jan 2008 | A1 |
| 20080027328 | Klopotek et al. | Jan 2008 | A1 |
| 20080091179 | Durkin et al. | Apr 2008 | A1 |
| 20080103563 | Powell | May 2008 | A1 |
| 20080119781 | King | May 2008 | A1 |
| 20080132914 | Bossard et al. | Jun 2008 | A1 |
| 20080139974 | Da Silva | Jun 2008 | A1 |
| 20080154161 | Abbott | Jun 2008 | A1 |
| 20080154183 | Baker et al. | Jun 2008 | A1 |
| 20080161799 | Stangenes et al. | Jul 2008 | A1 |
| 20080188840 | Johnson et al. | Aug 2008 | A1 |
| 20080193493 | Rhoades | Aug 2008 | A1 |
| 20080200861 | Shalev et al. | Aug 2008 | A1 |
| 20080208146 | Brandwein et al. | Aug 2008 | A1 |
| 20080214987 | Xu | Sep 2008 | A1 |
| 20080215068 | Hart et al. | Sep 2008 | A1 |
| 20080221548 | Danenberg et al. | Sep 2008 | A1 |
| 20080243039 | Rhoades | Oct 2008 | A1 |
| 20080287864 | Rosenberg | Nov 2008 | A1 |
| 20080300529 | Reinstein | Dec 2008 | A1 |
| 20080300552 | Cichocki et al. | Dec 2008 | A1 |
| 20090048557 | Yeshurun et al. | Feb 2009 | A1 |
| 20090053390 | Sakou et al. | Feb 2009 | A1 |
| 20090062815 | Karasiuk et al. | Mar 2009 | A1 |
| 20090099091 | Hantash | Apr 2009 | A1 |
| 20090099093 | Hantash | Apr 2009 | A1 |
| 20090124985 | Hasenoehrl et al. | May 2009 | A1 |
| 20090138026 | Wu | May 2009 | A1 |
| 20090177171 | Ignon et al. | Jul 2009 | A1 |
| 20090192442 | Ignon | Jul 2009 | A1 |
| 20090222023 | Boone, III et al. | Sep 2009 | A1 |
| 20090254014 | Son | Oct 2009 | A1 |
| 20100023003 | Mulholland | Jan 2010 | A1 |
| 20100036298 | Fuster | Feb 2010 | A1 |
| 20100045427 | Boone, III et al. | Feb 2010 | A1 |
| 20100048980 | De Jong et al. | Feb 2010 | A1 |
| 20100049177 | Boone, III et al. | Feb 2010 | A1 |
| 20100049210 | Boone, III et al. | Feb 2010 | A1 |
| 20100056847 | De Jong et al. | Mar 2010 | A1 |
| 20100217357 | Da Silva | Aug 2010 | A1 |
| 20100305495 | Anderson et al. | Dec 2010 | A1 |
| 20110054490 | Hart | Mar 2011 | A1 |
| 20110066162 | Cohen | Mar 2011 | A1 |
| 20110082415 | Ignon et al. | Apr 2011 | A1 |
| 20110264028 | Ramdas | Oct 2011 | A1 |
| 20110295273 | Waldron et al. | Dec 2011 | A1 |
| 20120041338 | Chickering, III et al. | Feb 2012 | A1 |
| 20120136374 | Karasiuk | May 2012 | A1 |
| 20120289885 | Cottrell et al. | Nov 2012 | A1 |
| 20120302929 | Tkachenko | Nov 2012 | A1 |
| 20130004230 | Kirk, III et al. | Jan 2013 | A1 |
| 20130018317 | Bobroff et al. | Jan 2013 | A1 |
| 20130066336 | Boone, III et al. | Mar 2013 | A1 |
| 20130096577 | Shadduck | Apr 2013 | A1 |
| 20130144207 | Gonon | Jun 2013 | A1 |
| 20130144280 | Eckhouse et al. | Jun 2013 | A1 |
| 20130158547 | David | Jun 2013 | A1 |
| 20130226269 | Eckhouse et al. | Aug 2013 | A1 |
| 20130261534 | Niezgoda et al. | Oct 2013 | A1 |
| 20140031801 | Giovannoli | Jan 2014 | A1 |
| 20140079686 | Barman et al. | Mar 2014 | A1 |
| 20140081251 | Giovannoli | Mar 2014 | A1 |
| 20140234004 | Thorpe et al. | Aug 2014 | A1 |
| 20140243589 | Rowan | Aug 2014 | A1 |
| 20140316492 | Min et al. | Oct 2014 | A1 |
| 20140343481 | Ignon | Nov 2014 | A1 |
| 20140343574 | Ignon et al. | Nov 2014 | A1 |
| 20140378887 | Chang et al. | Dec 2014 | A1 |
| 20150032047 | Ignon et al. | Jan 2015 | A1 |
| 20150039060 | Paulussen et al. | Feb 2015 | A1 |
| 20150230825 | Shadduck | Aug 2015 | A1 |
| 20150231379 | Ignon et al. | Aug 2015 | A1 |
| 20150265822 | Ignon et al. | Sep 2015 | A1 |
| 20150290442 | Ignon et al. | Oct 2015 | A1 |
| 20160015962 | Maragheh et al. | Jan 2016 | A1 |
| 20160018100 | Batt et al. | Jan 2016 | A1 |
| 20160038183 | Ignon et al. | Feb 2016 | A1 |
| 20160175609 | Dye et al. | Jun 2016 | A1 |
| 20160235257 | Daffer | Aug 2016 | A1 |
| 20160250415 | Yagi et al. | Sep 2016 | A1 |
| 20170036002 | Ignon et al. | Feb 2017 | A1 |
| 20170043150 | Kim | Feb 2017 | A1 |
| 20170065801 | Ignon et al. | Mar 2017 | A1 |
| 20170157419 | Jeong | Jun 2017 | A1 |
| 20170196759 | Palomaki et al. | Jul 2017 | A1 |
| 20170209894 | Sporrer | Jul 2017 | A1 |
| 20170291007 | Dubey et al. | Oct 2017 | A1 |
| 20170340356 | Presser et al. | Nov 2017 | A1 |
| 20180140329 | Beijens et al. | May 2018 | A1 |
| 20180185675 | Kern et al. | Jul 2018 | A1 |
| 20180318568 | Ignon et al. | Nov 2018 | A1 |
| 20180326191 | Bansal et al. | Nov 2018 | A1 |
| 20190070069 | Gertner et al. | Mar 2019 | A1 |
| 20190133642 | Ignon et al. | May 2019 | A1 |
| 20190143089 | Ignon et al. | May 2019 | A1 |
| 20190151637 | Groop et al. | May 2019 | A1 |
| 20190168016 | Anderson et al. | Jun 2019 | A1 |
| 20190209859 | Quisenberry et al. | Jul 2019 | A1 |
| 20190240502 | Anderson et al. | Aug 2019 | A1 |
| 20190336740 | Ignon et al. | Nov 2019 | A1 |
| 20190366067 | Ginggen et al. | Dec 2019 | A1 |
| 20200009007 | Shadduck | Jan 2020 | A1 |
| 20200016342 | Ignon | Jan 2020 | A1 |
| 20200030627 | Eltorai et al. | Jan 2020 | A1 |
| 20200101312 | Pai et al. | Apr 2020 | A1 |
| 20200114116 | Dubey et al. | Apr 2020 | A1 |
| 20200171288 | Ignon et al. | Jun 2020 | A1 |
| 20200171289 | Ignon et al. | Jun 2020 | A1 |
| 20200179220 | Jablow | Jun 2020 | A1 |
| 20200289161 | Scooros | Sep 2020 | A1 |
| 20200306555 | Ebbesson | Oct 2020 | A1 |
| 20200316270 | Dijkstra et al. | Oct 2020 | A1 |
| 20200330754 | Kim et al. | Oct 2020 | A1 |
| 20200338586 | Park | Oct 2020 | A1 |
| 20200390468 | Alexander | Dec 2020 | A1 |
| 20210085367 | Shadduck et al. | Mar 2021 | A1 |
| 20210145479 | Ignon et al. | May 2021 | A1 |
| 20210145480 | Ignon et al. | May 2021 | A1 |
| 20210145481 | Ignon et al. | May 2021 | A1 |
| 20210154453 | Ignon et al. | May 2021 | A1 |
| 20210154454 | Ignon et al. | May 2021 | A1 |
| 20210154455 | Ignon et al. | May 2021 | A1 |
| 20210177463 | Ignon et al. | Jun 2021 | A1 |
| 20210220631 | Ok et al. | Jul 2021 | A1 |
| 20210236342 | Long et al. | Aug 2021 | A1 |
| 20210236347 | Carver | Aug 2021 | A1 |
| 20210259914 | Holbert | Aug 2021 | A1 |
| 20210267625 | Carver | Sep 2021 | A1 |
| 20210268304 | Lee | Sep 2021 | A1 |
| 20210283421 | Kang et al. | Sep 2021 | A1 |
| 20210330356 | Del Rosario et al. | Oct 2021 | A1 |
| 20210353922 | Ignon et al. | Nov 2021 | A1 |
| 20210361525 | Park et al. | Nov 2021 | A1 |
| 20210370089 | Anash | Dec 2021 | A1 |
| 20210393478 | Bhatti | Dec 2021 | A1 |
| 20210393974 | Kim et al. | Dec 2021 | A1 |
| 20210393975 | Eltorai et al. | Dec 2021 | A1 |
| 20210395071 | Zubrum et al. | Dec 2021 | A1 |
| 20210402208 | Edgar | Dec 2021 | A1 |
| 20220001198 | Lee | Jan 2022 | A1 |
| 20220071491 | Bae et al. | Mar 2022 | A1 |
| 20220072332 | Park et al. | Mar 2022 | A1 |
| 20220087891 | Goodman et al. | Mar 2022 | A1 |
| 20220111198 | Jung | Apr 2022 | A1 |
| 20220125706 | Horinek et al. | Apr 2022 | A1 |
| 20220126014 | Cederna et al. | Apr 2022 | A1 |
| 20220176092 | Quan et al. | Jun 2022 | A1 |
| 20220211988 | Ignon et al. | Jul 2022 | A1 |
| 20220226668 | Lee et al. | Jul 2022 | A1 |
| 20220241107 | Kim et al. | Aug 2022 | A1 |
| 20220241146 | Jeong | Aug 2022 | A1 |
| 20220401714 | Quan et al. | Dec 2022 | A1 |
| 20230012684 | Ignon et al. | Jan 2023 | A1 |
| 20230018295 | Ignon et al. | Jan 2023 | A1 |
| 20230033217 | Ignon et al. | Feb 2023 | A1 |
| 20230033761 | Ignon et al. | Feb 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 400 305 | Dec 1995 | AT |
| 1 014 299 | May 1999 | AU |
| 2340 154 | Sep 2002 | CA |
| 107920948 | Apr 2018 | CN |
| 306995346 | Dec 2021 | CN |
| 59 95 21 | Jul 1934 | DE |
| 24 15 633 | Oct 1975 | DE |
| 33 38 057 | Aug 1984 | DE |
| 34 21 390 | Dec 1985 | DE |
| 234 608 | Apr 1986 | DE |
| 35 03 343 | Aug 1986 | DE |
| 83 30 191 | Jun 1987 | DE |
| 37 40 902 | Dec 1988 | DE |
| 42 37 940 | May 1993 | DE |
| 298 08 395 | Aug 1998 | DE |
| 10 2004 015815 | Nov 2005 | DE |
| 0 258 901 | Sep 1987 | EP |
| 0 564 392 | Mar 1993 | EP |
| 0 784 997 | Jul 1997 | EP |
| 1238643 | Apr 2000 | EP |
| 1 453 558 | Sep 2004 | EP |
| 2206483 | Jul 2010 | EP |
| 2544563 | Sep 2015 | EP |
| 2 106 780 | Mar 2016 | EP |
| 3 217 899 | May 2016 | EP |
| 2865867 | May 2016 | EP |
| 2240099 | Feb 2018 | EP |
| 3 302 319 | Apr 2018 | EP |
| 2967633 | Apr 2018 | EP |
| 3319573 | May 2018 | EP |
| 3 340 908 | Jul 2018 | EP |
| 2451367 | Jan 2020 | EP |
| 3388006 | Mar 2020 | EP |
| 2618797 | Apr 2020 | EP |
| 3237055 | Aug 2020 | EP |
| 3795204 | Mar 2021 | EP |
| 3437575 | Apr 2021 | EP |
| DES. 8794184-0001 | Dec 2021 | EP |
| 1 037 776 | Apr 1998 | ES |
| 2 712 172 | May 1995 | FR |
| 2 773 461 | Jul 1999 | FR |
| 1 372 609 | Oct 1974 | GB |
| 2306351 | May 1997 | GB |
| 553 076 | Dec 1956 | IT |
| 118 49 22 | Mar 1985 | IT |
| S55-034863 | Aug 1963 | JP |
| H05-042060 | Feb 1993 | JP |
| 1993-088552 | Dec 1993 | JP |
| 1997-294747 | Nov 1997 | JP |
| 2003-534881 | Nov 2003 | JP |
| 2003-339713 | Dec 2003 | JP |
| 2004-275721 | Oct 2004 | JP |
| 2006-503627 | Feb 2006 | JP |
| 2006-204767 | Oct 2006 | JP |
| 2010042243 | Feb 2010 | JP |
| 2012527967 | Nov 2012 | JP |
| 5508285 | Mar 2014 | JP |
| D1581877 | Jul 2017 | JP |
| 2018-527052 | Sep 2018 | JP |
| 20-0280320 | Jul 2002 | KR |
| 10-20070070173 | Jul 2007 | KR |
| 10-2018-0030607 | Mar 2018 | KR |
| 10-1836310 | Mar 2018 | KR |
| D214226 | Sep 2021 | TW |
| WO 1994024980 | Nov 1994 | WO |
| WO 1997011650 | Mar 1997 | WO |
| WO 2000015300 | Mar 2000 | WO |
| WO 0079540 | Dec 2000 | WO |
| WO 200193931 | Dec 2001 | WO |
| WO 2003073917 | Sep 2003 | WO |
| WO 2004037098 | May 2004 | WO |
| WO 2005061042 | Jul 2005 | WO |
| WO 2005070313 | Aug 2005 | WO |
| WO 2006018731 | Feb 2006 | WO |
| WO 2006031413 | Mar 2006 | WO |
| WO 2007114904 | Oct 2007 | WO |
| WO 2008012324 | Jan 2008 | WO |
| WO 2009088884 | Jul 2009 | WO |
| WO 2009097451 | Aug 2009 | WO |
| WO 2010068960 | Jun 2010 | WO |
| WO 2011006009 | Jan 2011 | WO |
| WO 2011110840 | Sep 2011 | WO |
| WO 2012145667 | Oct 2012 | WO |
| WO 2013030117 | Mar 2013 | WO |
| WO 2014091035 | Jun 2014 | WO |
| WO 2014151104 | Sep 2014 | WO |
| WO 2016052818 | Apr 2016 | WO |
| WO 2016106396 | Jun 2016 | WO |
| WO 2017007939 | Jan 2017 | WO |
| WO 2017111481 | Jun 2017 | WO |
| WO 2021018765 | Feb 2021 | WO |
| WO 2021113343 | Jun 2021 | WO |
| WO 2022099318 | May 2022 | WO |
| Entry |
|---|
| Cox III et al., Decreased Splatter in Dermabrasion, Arch Facial Plastic Surgery, Jan.-Mar. 2000, vol. 2, pp. 23-26. |
| Ditre et al., Effect of α-hydroxy acids on photoaged skin: A pilot clinical, histologic, and ultrastructural study, Journal of American Academy of Dermatology, Feb. 1996, vol. 34, No. 2, Part 1, pp. 187-195. |
| Harris et al., Combining Manual Dermasanding with Low Strength Trichloroacetic Acid to Improve Antinically Injured Skin, The Journal of Dermatologic Surgery and Oncology, Jul. 1994, vol. 20, No. 7, pp. 436-442. |
| Hydrafacial® Tower—User guide. Edge Systems. Revised Jun. 23, 2016. Page No. 16. |
| Microdermabrader Pepita Instruction Manual, Mattioli Engineering S.R.L., Pep_USA2.doc Rev 1.1, Sep. 29, 1997. |
| International Search Report and Written Opinion for related PCT appl. PCT/US14/24992 dated Jul. 21, 2014. |
| U.S. Appl. No. U.S. Appl. No. 11/417,396 (U.S. Pat. No. 7,678,120), filed May 3, 2006, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 13/620,164, filed Sep. 14, 2012, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 15/953,337, filed Apr. 13, 2018, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 16/517,268, filed Jul. 19, 2019, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 17/165,820, filed Feb. 2, 2021, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 29/679,299, filed Feb. 4, 2019, Skin Treatment System. |
| U.S. Appl. No. 29/679,306, filed Feb. 4, 2019, Handpiece Assembly Tip. |
| U.S. Appl. No. 29/679,302, filed Feb. 4, 2019, Handpiece Assembly Tip. |
| U.S. Appl. No. 17/163,199, filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/163,237, filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/163,240, filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 16/040,397, filed Jul. 19, 2018, Devices and Methods for the Skin. |
| U.S. Appl. No. 16/246,306, filed Jan. 11, 2019, Devices and Methods for Treating the Skin Using a Porous Member. |
| U.S. Appl. No. 15/204,939, filed Jul. 7, 2016, Devices, Systems and Methods for Promoting Hair Growth. |
| U.S. Appl. No. 09/648,025 (U.S. Pat. No. 6,641,591), filed Aug. 25, 2000, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 10/699,747 (U.S. Pat. No. 7,789,886), filed Nov. 3, 2003, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 11/739,615 (U.S. Pat. No. 8,337,513), filed Apr. 24, 2007, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 11/417,709 (U.S. Pat. No. 8,066,716), filed May 3, 2006, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 11/417,396 (U.S. Pat. No. 7,678,120), filed May 3, 2006, Instruments and Techniques for Controlled Removal of Epidermal Layers. |
| U.S. Appl. No. 14/702,509 (U.S. Pat. No. 9,775,646), filed May 1, 2015, Devices and Systems for Treating the Skin Using Vacuum. |
| U.S. Appl. No. 14/702,486 (U.S. Pat. No. 9,468,464), filed May 1, 2015, Methods for Treating the Skin Using Vacuum. |
| U.S. Appl. No. 11/392,348 (U.S. Pat. No. 8,048,089), filed Mar. 29, 2006, Apparatus and Methods for Treating the Skin. |
| U.S. Appl. No. 13/267,554 (U.S. Pat. No. 9,474,886), filed Oct. 6, 2011, Removable Tips for Skin Treatment Systems. |
| U.S. Appl. No. 14/698,673 (U.S. Pat. No. 9,550,052), filed Apr. 28, 2015, Console System for the Treatment of Skin. |
| U.S. Appl. No. 14/698,713 (U.S. Pat. No. 9,662,482), filed Apr. 28, 2015, Methods and Systems for Extraction of Materials From Skin. |
| U.S. Appl. No. 14/700,789 (U.S. Pat. No. 9,814,868), filed Apr. 30, 2015, Tip With Embedded Materials for Skin Treatment. |
| U.S. Appl. No. 15/660,750 (U.S. Pat. No. 10/357,641), filed Jul. 26, 2017, Tips for Skin Treatment Device. |
| U.S. Appl. No. 15/660,777 (U.S. Pat. No. 10/357,642), filed Jul. 26, 2017, Removable Tips for Use With Skin Treatment Systems. |
| U.S. Appl. No. 16/517,268 (U.S. Pat. No. 11,446,477), filed Jul. 19, 2019, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 17/165,820 (U.S. Pat. No. 11,547,840), filed Feb. 2, 2021, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 17/165,807, filed Feb. 2, 2021, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 18/094,884, filed Jan. 9, 2023, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 09/294,254 (U.S. Pat. No. 6,162,232), filed Apr. 19, 1999, Instruments and Techniques for High-Velocity Fluid Abrasion of Epidermal Layers With Skin Cooling. |
| U.S. Appl. No. 09/475,480 (U.S. Pat. No. 6,299,620), filed Dec. 30, 1999, Instruments and Techniques for Inducing Neocollagenesis in Skin Treatments. |
| U.S. Appl. No. 09/475,479 (U.S. Pat. No. 6,387,103), filed Dec. 30, 1999, Instruments and Techniques for Inducing Neocollagenesis in Skin Treatments. |
| U.S. Appl. No. 11/370,200, filed Mar. 7, 2006, Microdermabrasion Method and Apparatus. |
| U.S. Appl. No. 12/362,353 (U.S. Pat. No. 9,056,193), filed Jan. 29, 2009, Apparatus and Method for Treating the Skin. |
| U.S. Appl. No. 14/734,995 (U.S. Pat. No. 11,020,577), filed Jun. 9, 2015, Devices and Systems for Treating Skin Surfaces. |
| U.S. Appl. No. 17/332,897, filed May 27, 2021, Devices, Systems, and Methods for Treating the Skin. |
| U.S. Appl. No. 17/952,569, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin. |
| U.S. Appl. No. 17/952,665, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin. |
| U.S. Appl. No. 12/832,663 (U.S. Pat. No. 8,814,836), filed Jul. 8, 2010, Devices, Systems and Methods for Treating the Skin Using Time-Release Substances. |
| U.S. Appl. No. 14/455,762 (U.S. Pat. No. 9,642,997), filed Aug. 8, 2014, Devices for Treating Skin Using Treatment Materials Located Along a Tip. |
| U.S. Appl. No. 15/588,102 (U.S. Pat. No. 10,556,097), filed May 5, 2017, Devices for Treating Skin Using Treatment Materials Located Along a Tip. |
| U.S. Appl. No. 16/784,850, filed Feb. 7, 2020, Devices and Methods for Treating Skin. |
| U.S. Appl. No. 12/346,582 (U.S. Pat. No. 8,343,116), filed Dec. 30, 2008, Apparatus and Method for Treating the Skin. |
| U.S. Appl. No. 13/620,376 (U.S. Pat. No. 9,486,615), filed Sep. 14, 2012, Microdermabrasion Apparatus and Method. |
| U.S. Appl. No. 15/344,357 (U.S. Pat. No. 10,556,096), filed Nov. 4, 2016, Devices and Methods for Skin Treatment. |
| U.S. Appl. No. 16/784,044, filed Feb. 6, 2020, Devices and Methods for Skin Treatment. |
| U.S. Appl. No. 09/540,945 (U.S. Pat. No. 6,592,595), filed Mar. 31, 2000, Microdermabrasion and Suction Massage Apparatus and Method. |
| U.S. Appl. No. 09/698,409 (U.S. Pat. No. 6,527,783), filed Oct. 27, 2000, Microdermabrasion and Suction Massage Apparatus and Method. |
| U.S. Appl. No. 10/177,173 (U.S. Pat. No. 6,673,082), filed Jun. 20, 2002, Microdermabrasion Handpiece With Supply and Return Lumens. |
| U.S. Appl. No. 10/315,478 (U.S. Pat. No. 6,942,649), filed Dec. 10, 2002, Microdermabrasion Fluid Application System and Method. |
| U.S. Appl. No. 09/699,220 (U.S. Pat. No. 6,629,983), filed Oct. 27, 2000, Apparatus and Method for Skin/Surface Abrasion. |
| U.S. Appl. No. 14/211,089 (U.S. Pat. No. 10,238,812), filed Mar. 14, 2014, Skin Treatment Systems and Methods Using Needles. |
| U.S. Appl. No. 16/363,310, filed Mar. 25, 2019, Skin Treatment Systems and Methods Using Needles. |
| U.S. Appl. No. 14/211,290 (U.S. Pat. No. 9,566,088), filed Mar. 14, 2014, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 15/430,209 (U.S. Pat. No. 10,251,675), filed Feb. 10, 2017, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 16/376,956 (present application), filed Apr. 5, 2019, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/952,721, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin. |
| U.S. Appl. No. 17/952,676, filed Sep. 26, 2022, Devices, Systems, and Methods for Treating the Skin. |
| U.S. Appl. No. 14/774,641 (U.S. Pat. No. 10,172,644), filed Sep. 10, 2015, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 16/241,572 (U.S. Pat. No. 10,993,743), filed Jan. 7, 2019, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/163,128, filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/163,199 (U.S. Pat. No. 11,517,350), filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/163,237 (U.S. Pat. No. 11,202,657), filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 17/163,240 (U.S. Pat. No. 11,213,321), filed Jan. 29, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 14/998,375 (U.S. Pat. No. 9,498,610), filed Dec. 23, 2015, Devices and Methods for Treating the Skin Using a Rollerball or a Wicking Member. |
| U.S. Appl. No. 15/354,754 (U.S. Pat. No. 10,035,007), filed Nov. 17, 2016, Devices and Methods for Treating the Skin. |
| U.S. Appl. No. 16/040,397, filed Jul. 19, 2018, Devices and Methods for Treating the Skin. |
| U.S. Appl. No. 17/164,580, filed Feb. 1, 2021, Devices and Methods for Treating the Skin. |
| U.S. Appl. No. 15/498,416 (U.S. Pat. No. 10,179,229), filed Apr. 26, 2017, Devices and Methods for Treating the Skin Using a Porous Member. |
| U.S. Appl. No. 16/246,306 (U.S. Pat. No. 11,224,728), filed Jan. 11, 2019, Devices and Methods for Treating the Skin Using a Porous Member. |
| U.S. Appl. No. 17/576,888, filed Jan. 14, 2022, Devices and Methods for Treating the Skin. |
| U.S. Appl. No. 15/204,939 (U.S. Pat. No. 11,241,357), filed Jul. 7, 2016, Devices, Systems and Methods for Promoting Hair Growth. |
| U.S. Appl. No. 17/592,432, filed Feb. 3, 2022, Devices, Systems and Methods for Improving Scalp Health. |
| U.S. Appl. No. 63/254,455, filed Oct. 11, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 63/432,691, filed Dec. 14, 2022, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 63/243,053, filed Sep. 10, 2021, Devices, Systems and Methods for Treating the Skin. |
| U.S. Appl. No. 29/811,066, filed Oct. 11, 2021, Skin Treatment System. |
| U.S. Appl. No. 29/807,430, filed Sep. 10, 2021, Skin Treatment Device. |
| U.S. Appl. No. 29/807,428, filed Sep. 10, 2021, Container for a Skin Treatment Device. |
| U.S. Appl. No. 29/829,476, filed Mar. 4, 2022, Light Therapy Device for Skin Care. |
| U.S. Appl. No. 29/811,070, filed Oct. 11, 2021, Skin Treatment Tip. |
| U.S. Appl. No. 29/,826,153, filed Feb. 9, 2022, Dual Treating Device for Treating Acne or Wrinkles. |
| U.S. Appl. No. 29/854,067, filed Sep. 21, 2022, Treatment Device for Skin. |
| U.S. Appl. No. 29/884,441, filed Feb. 10, 2023, Skin Treatment Tip. |
| Amazon, FAZJEUNE 7 Color LED Light, LED Face Mask Skin Rejevenation PDT Photon Facial Skin Care Mask Skin Tightening Lamp SPA Face Device Beauty Salon Equipment Anti-aging Remove Wrinkle, Customer reviewed on Sep. 2020, retrieved from internet at https://www.amazon.com/FAZJEUNE-Rejuvenation-Tightening-Equipment-Anti-aging/dp/B08B4M8RQQ/ref=psdc_11061121_t3_B08ZSPZSF4. |
| Number | Date | Country | |
|---|---|---|---|
| 20190223914 A1 | Jul 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61791157 | Mar 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15430209 | Feb 2017 | US |
| Child | 16376956 | US | |
| Parent | 14211290 | Mar 2014 | US |
| Child | 15430209 | US |
